CINXE.COM
Search
<!DOCTYPE html> <html lang="en" class="no-js"> <head> <meta charset="UTF-8"> <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes"> <title>Search</title> <meta id="meta-title" property="citation_title" content="Search"/> <meta id="og-title" property="og:title" content="Search"/> <meta name="twitter:widgets:autoload" content="off"/> <meta name="twitter:dnt" content="on"/> <meta name="twitter:widgets:csp" content="on"/> <meta name="google-site-verification" content="lQbRRf0vgPqMbnbCsgELjAjIIyJjiIWo917M7hBshvI"/> <meta id="og-image" property="og:image" content="https://escholarship.org/images/escholarship-facebook2.jpg"/> <meta id="og-image-width" property="og:image:width" content="1242"/> <meta id="og-image-height" property="og:image:height" content="1242"/> <link rel="stylesheet" href="/css/main-62e3023ddd136de2.css"> <link rel="resource" type="application/l10n" href="/node_modules/pdfjs-embed2/dist/locale/locale.properties"> <noscript><style> .jsonly { display: none } </style></noscript> <!-- Matomo --> <!-- TBD Configure Matomo for SPA https://developer.matomo.org/guides/spa-tracking --> <script> var _paq = window._paq = window._paq || []; /* tracker methods like "setCustomDimension" should be called before "trackPageView" */ _paq.push(['trackPageView']); _paq.push(['enableLinkTracking']); (function() { var u="//matomo.cdlib.org/"; _paq.push(['setTrackerUrl', u+'matomo.php']); _paq.push(['setSiteId', '7']); var d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src=u+'matomo.js'; s.parentNode.insertBefore(g,s); })(); </script> <!-- End Matomo Code --> </head> <body> <div id="main"><div data-reactroot=""><div class="body"><a href="#maincontent" class="c-skipnav">Skip to main content</a><div class="l_search"><div><div style="margin-top:-10px"></div><header id="#top" class="c-header"><a class="c-header__logo2" href="/"><picture><source srcSet="/images/logo_eschol-small.svg" media="(min-width: 870px)"/><img src="/images/logo_eschol-mobile.svg" alt="eScholarship"/></picture><div class="c-header__logo2-tagline">Open Access Publications from the University of California</div></a><div class="c-header__search"><form class="c-search1"><label class="c-search1__label" for="c-search1__field">search</label><input type="search" id="c-search1__field" name="q" class="c-search1__field" placeholder="Search over 500,000 items" autoCapitalize="off" value="author:Perkins, Diana"/><button type="submit" class="c-search1__submit-button" aria-label="submit search"></button><button type="button" class="c-search1__search-close-button" aria-label="close search field"></button></form></div><button class="c-header__search-open-button" aria-label="open search field"></button></header></div><div class="c-navbar"><nav class="c-nav"><details open="" class="c-nav__main"><summary class="c-nav__main-button">Menu</summary><ul class="c-nav__main-items"><li><details class="c-nav__sub"><summary class="c-nav__sub-button">About eScholarship</summary><div class="c-nav__sub-items"><button class="c-nav__sub-items-button" aria-label="return to menu">Main Menu</button><ul><li><a href="/aboutEschol">About eScholarship</a></li><li><a href="/repository">eScholarship Repository</a></li><li><a href="/publishing">eScholarship Publishing</a></li><li><a href="/policies">Site policies</a></li><li><a href="/terms">Terms of Use and Copyright Information</a></li><li><a href="/privacyPolicy">Privacy statement</a></li></ul></div></details></li><li><details class="c-nav__sub"><summary class="c-nav__sub-button">Campus Sites</summary><div class="c-nav__sub-items"><button class="c-nav__sub-items-button" aria-label="return to menu">Main Menu</button><ul><li><a href="/uc/ucb">UC Berkeley</a></li><li><a href="/uc/ucd">UC Davis</a></li><li><a href="/uc/uci">UC Irvine</a></li><li><a href="/uc/ucla">UCLA</a></li><li><a href="/uc/ucm">UC Merced</a></li><li><a href="/uc/ucr">UC Riverside</a></li><li><a href="/uc/ucsd">UC San Diego</a></li><li><a href="/uc/ucsf">UCSF</a></li><li><a href="/uc/ucsb">UC Santa Barbara</a></li><li><a href="/uc/ucsc">UC Santa Cruz</a></li><li><a href="/uc/ucop">UC Office of the President</a></li><li><a href="/uc/lbnl">Lawrence Berkeley National Laboratory</a></li><li><a href="/uc/anrcs">UC Agriculture & Natural Resources</a></li></ul></div></details></li><li><a href="/ucoapolicies">UC Open Access Policies</a></li><li><a href="/publishing">eScholarship Publishing</a></li></ul></details></nav></div><form id="facetForm" class="c-columns"><aside><div><div class="c-filter"><h1 class="c-filter__heading">Your search: "author:Perkins, Diana"</h1><input type="hidden" name="q" value="author:Perkins, Diana"/><div class="c-filter__results">137<!-- --> results</div><div class="c-filter__inactive-note">No filters applied</div><details class="c-filter__active" open=""><summary><span><strong></strong> filter<!-- -->s<!-- --> applied</span></summary><button class="c-filter__clear-all">clear all</button><ul class="c-filter__active-list"></ul></details><a href="https://help.escholarship.org/support/solutions/articles/9000148939-using-advanced-search-beta-" class="c-filter__tips">Search tips</a></div><div class="c-refine--has-drawer"><button class="c-refine__button--open">Refine Results</button><button class="c-refine__button--close" hidden="">Back to Results</button><div class="c-refine__drawer--closed"><details class="c-facetbox" open=""><summary class="c-facetbox__summary"><span id="facetbox0">Type of Work</span></summary><fieldset aria-labelledby="facetbox0"><ul class="c-checkbox"><li class=""><input type="checkbox" id="type_of_work-article" class="c-checkbox__input" name="type_of_work" value="article"/><label for="type_of_work-article" class="c-checkbox__label">Article<!-- --> (<!-- -->137<!-- -->)</label></li><li class=""><input type="checkbox" id="type_of_work-monograph" class="c-checkbox__input" name="type_of_work" value="monograph"/><label for="type_of_work-monograph" class="c-checkbox__label">Book<!-- --> (<!-- -->0<!-- -->)</label></li><li class=""><input type="checkbox" id="type_of_work-dissertation" class="c-checkbox__input" name="type_of_work" value="dissertation"/><label for="type_of_work-dissertation" class="c-checkbox__label">Theses<!-- --> (<!-- -->0<!-- -->)</label></li><li class=""><input type="checkbox" id="type_of_work-multimedia" class="c-checkbox__input" name="type_of_work" value="multimedia"/><label for="type_of_work-multimedia" class="c-checkbox__label">Multimedia<!-- --> (<!-- -->0<!-- -->)</label></li></ul></fieldset></details><details class="c-facetbox" open=""><summary class="c-facetbox__summary"><span id="facetbox1">Peer Review</span></summary><fieldset aria-labelledby="facetbox1"><ul class="c-checkbox"><li class=""><input type="checkbox" id="peer_reviewed-1" class="c-checkbox__input" name="peer_reviewed" value="1"/><label for="peer_reviewed-1" class="c-checkbox__label">Peer-reviewed only<!-- --> (<!-- -->137<!-- -->)</label></li></ul></fieldset></details><details class="c-facetbox"><summary class="c-facetbox__summary"><span id="facetbox2">Supplemental Material</span></summary><fieldset aria-labelledby="facetbox2"><ul class="c-checkbox--2column"><li class=""><input type="checkbox" id="supp_file_types-video" class="c-checkbox__input" name="supp_file_types" value="video"/><label for="supp_file_types-video" class="c-checkbox__label">Video<!-- --> (<!-- -->0<!-- -->)</label></li><li class=""><input type="checkbox" id="supp_file_types-audio" class="c-checkbox__input" name="supp_file_types" value="audio"/><label for="supp_file_types-audio" class="c-checkbox__label">Audio<!-- --> (<!-- -->0<!-- -->)</label></li><li class=""><input type="checkbox" id="supp_file_types-images" class="c-checkbox__input" name="supp_file_types" value="images"/><label for="supp_file_types-images" class="c-checkbox__label">Images<!-- --> (<!-- -->0<!-- -->)</label></li><li class=""><input type="checkbox" id="supp_file_types-zip" class="c-checkbox__input" name="supp_file_types" value="zip"/><label for="supp_file_types-zip" class="c-checkbox__label">Zip<!-- --> (<!-- -->0<!-- -->)</label></li><li class=""><input type="checkbox" id="supp_file_types-other_files" class="c-checkbox__input" name="supp_file_types" value="other files"/><label for="supp_file_types-other_files" class="c-checkbox__label">Other files<!-- --> (<!-- -->0<!-- -->)</label></li></ul></fieldset></details><details class="c-facetbox"><summary class="c-facetbox__summary"><span id="facetbox3">Publication Year</span></summary><fieldset aria-labelledby="facetbox3"><div class="c-pubyear"><div class="c-pubyear__field"><label for="c-pubyear__textfield1">From:</label><input type="text" id="c-pubyear__textfield1" name="pub_year_start" maxLength="4" placeholder="1900" value=""/></div><div class="c-pubyear__field"><label for="c-pubyear__textfield2">To:</label><input type="text" id="c-pubyear__textfield2" name="pub_year_end" maxLength="4" placeholder="2024" value=""/></div><button class="c-pubyear__button">Apply</button></div></fieldset></details><details class="c-facetbox"><summary class="c-facetbox__summary"><span id="facetbox4">Campus</span></summary><fieldset aria-labelledby="facetbox4"><ul class="c-checkbox"><li class=""><input type="checkbox" id="campuses-ucb" class="c-checkbox__input" name="campuses" value="ucb"/><label for="campuses-ucb" class="c-checkbox__label">UC Berkeley<!-- --> (<!-- -->0<!-- -->)</label></li><li class=""><input type="checkbox" id="campuses-ucd" class="c-checkbox__input" name="campuses" value="ucd"/><label for="campuses-ucd" class="c-checkbox__label">UC Davis<!-- --> (<!-- -->1<!-- -->)</label></li><li class=""><input type="checkbox" id="campuses-uci" class="c-checkbox__input" name="campuses" value="uci"/><label for="campuses-uci" class="c-checkbox__label">UC Irvine<!-- --> (<!-- -->11<!-- -->)</label></li><li class=""><input type="checkbox" id="campuses-ucla" class="c-checkbox__input" name="campuses" value="ucla"/><label for="campuses-ucla" class="c-checkbox__label">UCLA<!-- --> (<!-- -->101<!-- -->)</label></li><li class=""><input type="checkbox" id="campuses-ucm" class="c-checkbox__input" name="campuses" value="ucm"/><label for="campuses-ucm" class="c-checkbox__label">UC Merced<!-- --> (<!-- -->0<!-- -->)</label></li><li class=""><input type="checkbox" id="campuses-ucr" class="c-checkbox__input" name="campuses" value="ucr"/><label for="campuses-ucr" class="c-checkbox__label">UC Riverside<!-- --> (<!-- -->0<!-- -->)</label></li><li class=""><input type="checkbox" id="campuses-ucsd" class="c-checkbox__input" name="campuses" value="ucsd"/><label for="campuses-ucsd" class="c-checkbox__label">UC San Diego<!-- --> (<!-- -->127<!-- -->)</label></li><li class=""><input type="checkbox" id="campuses-ucsf" class="c-checkbox__input" name="campuses" value="ucsf"/><label for="campuses-ucsf" class="c-checkbox__label">UCSF<!-- --> (<!-- -->92<!-- -->)</label></li><li class=""><input type="checkbox" id="campuses-ucsb" class="c-checkbox__input" name="campuses" value="ucsb"/><label for="campuses-ucsb" class="c-checkbox__label">UC Santa Barbara<!-- --> (<!-- -->4<!-- -->)</label></li><li class=""><input type="checkbox" id="campuses-ucsc" class="c-checkbox__input" name="campuses" value="ucsc"/><label for="campuses-ucsc" class="c-checkbox__label">UC Santa Cruz<!-- --> (<!-- -->3<!-- -->)</label></li><li class=""><input type="checkbox" id="campuses-ucop" class="c-checkbox__input" name="campuses" value="ucop"/><label for="campuses-ucop" class="c-checkbox__label">UC Office of the President<!-- --> (<!-- -->0<!-- -->)</label></li><li class=""><input type="checkbox" id="campuses-lbnl" class="c-checkbox__input" name="campuses" value="lbnl"/><label for="campuses-lbnl" class="c-checkbox__label">Lawrence Berkeley National Laboratory<!-- --> (<!-- -->7<!-- -->)</label></li><li class=""><input type="checkbox" id="campuses-anrcs" class="c-checkbox__input" name="campuses" value="anrcs"/><label for="campuses-anrcs" class="c-checkbox__label">UC Agriculture & Natural Resources<!-- --> (<!-- -->0<!-- -->)</label></li></ul></fieldset></details><details class="c-facetbox"><summary class="c-facetbox__summary"><span id="facetbox5">Department</span></summary><fieldset aria-labelledby="facetbox5"><ul class="c-checkbox"><li class=""><input type="checkbox" id="departments-ucsdsom" class="c-checkbox__input" name="departments" value="ucsdsom"/><label for="departments-ucsdsom" class="c-checkbox__label">School of Medicine<!-- --> (<!-- -->125<!-- -->)</label></li><li class=""><input type="checkbox" id="departments-ucsdpsych" class="c-checkbox__input" name="departments" value="ucsdpsych"/><label for="departments-ucsdpsych" class="c-checkbox__label">Department of Psychiatry, UCSD<!-- --> (<!-- -->116<!-- -->)</label></li><li class=""><input type="checkbox" id="departments-uclapsych" class="c-checkbox__input" name="departments" value="uclapsych"/><label for="departments-uclapsych" class="c-checkbox__label">UCLA Department of Psychology<!-- --> (<!-- -->92<!-- -->)</label></li><li class=""><input type="checkbox" id="departments-lbnl_ees" class="c-checkbox__input" name="departments" value="lbnl_ees"/><label for="departments-lbnl_ees" class="c-checkbox__label">Earth & Environmental Sciences<!-- --> (<!-- -->5<!-- -->)</label></li><li class=""><input type="checkbox" id="departments-lbnl_cs" class="c-checkbox__input" name="departments" value="lbnl_cs"/><label for="departments-lbnl_cs" class="c-checkbox__label">Computing Sciences<!-- --> (<!-- -->3<!-- -->)</label></li><li class=""><input type="checkbox" id="departments-lbnl_bs" class="c-checkbox__input" name="departments" value="lbnl_bs"/><label for="departments-lbnl_bs" class="c-checkbox__label">BioSciences<!-- --> (<!-- -->1<!-- -->)</label></li></ul></fieldset></details><details class="c-facetbox"><summary class="c-facetbox__summary"><span id="facetbox6">Journal</span></summary><fieldset aria-labelledby="facetbox6"><ul class="c-checkbox"></ul></fieldset></details><details class="c-facetbox"><summary class="c-facetbox__summary"><span id="facetbox7">Discipline</span></summary><fieldset aria-labelledby="facetbox7"><ul class="c-checkbox"></ul></fieldset></details><details class="c-facetbox"><summary class="c-facetbox__summary"><span id="facetbox8">Reuse License</span></summary><fieldset aria-labelledby="facetbox8"><ul class="c-checkbox"><li class="c-checkbox__attrib-cc-by"><input type="checkbox" id="rights-CC_BY" class="c-checkbox__input" name="rights" value="CC BY"/><label for="rights-CC_BY" class="c-checkbox__label">BY - Attribution required<!-- --> (<!-- -->3<!-- -->)</label></li></ul></fieldset></details></div></div><button type="submit" id="facet-form-submit" style="display:none">Search</button></div></aside><main id="maincontent"><section class="o-columnbox1"><header><h2 class="o-columnbox1__heading" aria-live="polite">Scholarly Works (<!-- -->137 results<!-- -->)</h2></header><div class="c-sortpagination"><div class="c-sort"><div class="o-input__droplist1"><label for="c-sort1">Sort By:</label><select name="sort" id="c-sort1" form="facetForm"><option selected="" value="rel">Relevance</option><option value="a-title">A-Z By Title</option><option value="z-title">Z-A By Title</option><option value="a-author">A-Z By Author</option><option value="z-author">Z-A By Author</option><option value="asc">Date Ascending</option><option value="desc">Date Descending</option></select></div><div class="o-input__droplist1 c-sort__page-input"><label for="c-sort2">Show:</label><select name="rows" id="c-sort2" form="facetForm"><option selected="" value="10">10</option><option value="20">20</option><option value="30">30</option><option value="40">40</option><option value="50">50</option><option value="100">100</option></select></div></div><input type="hidden" name="start" form="facetForm" value="0"/><nav class="c-pagination--next"><ul><li><a href="" aria-label="you are on result set 1" class="c-pagination__item--current">1</a></li><li><a href="" aria-label="go to result set 2" class="c-pagination__item">2</a></li><li><a href="" aria-label="go to result set 3" class="c-pagination__item">3</a></li><li><a href="" aria-label="go to result set 4" class="c-pagination__item">4</a></li><li><a href="" aria-label="go to result set 14" class="c-pagination__item">14</a></li><li class="c-pagination__next"><a href="" aria-label="go to Next result set">Next</a></li></ul></nav></div><section class="c-scholworks"><div class="c-scholworks__main-column"><ul class="c-scholworks__tag-list"><li class="c-scholworks__tag-article">Article</li><li class="c-scholworks__tag-peer">Peer Reviewed</li></ul><div><h3 class="c-scholworks__heading"><a href="/uc/item/85g271k0"><div class="c-clientmarkup">39.1 DNA METHYLATION OF IMMUNE CELLS IN PERSONS AT CLINICAL HIGH RISK FOR PSYCHOSIS</div></a></h3></div><div class="c-authorlist"><ul class="c-authorlist__list"><li class="c-authorlist__begin"><a href="/search/?q=author%3APerkins%2C%20Diana">Perkins, Diana</a>; </li><li><a href="/search/?q=author%3AClark%2C%20Jeffries">Clark, Jeffries</a>; </li><li><a href="/search/?q=author%3AAddington%2C%20Jean">Addington, Jean</a>; </li><li><a href="/search/?q=author%3ABeardon%2C%20Carrie">Beardon, Carrie</a>; </li><li><a href="/search/?q=author%3ACadenhead%2C%20Kristin">Cadenhead, Kristin</a>; </li><li><a href="/search/?q=author%3ACannon%2C%20Tyrone">Cannon, Tyrone</a>; </li><li><a href="/search/?q=author%3ACornblatt%2C%20Barbara">Cornblatt, Barbara</a>; </li><li><a href="/search/?q=author%3AMathalon%2C%20Daniel">Mathalon, Daniel</a>; </li><li><a href="/search/?q=author%3AMcGlashan%2C%20Thomas">McGlashan, Thomas</a>; </li><li><a href="/search/?q=author%3ASeidman%2C%20Larry">Seidman, Larry</a>; </li><li><a href="/search/?q=author%3ATsuang%2C%20Ming">Tsuang, Ming</a>; </li><li><a href="/search/?q=author%3AWalker%2C%20Elaine">Walker, Elaine</a>; </li><li class="c-authorlist__end"><a href="/search/?q=author%3AWoods%2C%20Scott">Woods, Scott</a> </li></ul></div><div class="c-scholworks__publication"><a href="/uc/ucsd_postprints">UC San Diego Previously Published Works</a> (<!-- -->2018<!-- -->)</div><div class="c-scholworks__abstract"><div class="c-clientmarkup">Abstract <h3>Background</h3> A dysregulated immune system is implicated in the development of psychotic disorders. Persons with schizophrenia have altered levels of circulating immune cell signaling molecules (cytokines), and elevation of specific cytokines predict conversion to psychosis in persons at clinical high risk. Whether these peripheral signals are a causal or a secondary phenomenon is unclear. But, subpopulations of circulating immune cells do regulate the brain from meningeal and perivascular locations influencing cognition, mood, and behavior, and thus may be relevant to schizophrenia vulnerability. Hematopoietic stem cells in the bone marrow differentiate into cascading subtypes depending on signals from other organs, especially the brain. For example, a monocyte subpopulation emerges with repeated social defeat that establish the persistence of anxiety-like behaviors; blocking their release or inhibiting their attachment to brain vascular endothelium prevents the emergence of anxiety-like behaviors. In humans, a similar monocyte subpopulation is associated with social isolation and other adversities including low SES, chronic stress, and bereavement. <h3>Methods</h3> The North American Prodrome Longitudinal Study (NAPLS2) is an eight-site observational study of predictors and mechanisms of conversion to psychosis The full cohort includes 763 at clinical high risk (CHR) based on the Criteria of Prodromal State (COPS) and 279 demographically similar unaffected comparison (UC) subjects. Methylation of whole blood DNA collected in PAXgene tubes at baseline was analyzed with the Illumina 450k array in a subgroup of 59 subjects who converted to psychosis (CHR-C), 84 CHR subjects followed for 2 years who did not develop psychosis (CHR-NC) and 67 unaffected subjects (UC). Our analyses focused on methylation of promoter regions of genes, associated with gene expression. Classifier construction used Coarse Approximation Linear Function (CALF) with bootstrapping of 1000 random 80% subsets with replacement to determine statistical likelihood. <h3>Results</h3> We found highly overlapping sets of differentially methylated promoter regions in CHR-C subjects compared to CHR-NC and to UC subjects. A set of 10 markers correctly classified CHR-C and CHR-NC subjects with high accuracy (AUC=0.94, 95% CI 0.89–0.98). Included was SIRT1, a gene that is upregulated with HSV reactivation. <h3>Discussion</h3> Circulating immune cells excerpt powerful influences on mood, cognition and behavior. An obvious example is the experience of most human with “sickness syndrome”, characterized by apathy, avolition, and withdrawal, and triggered by immune-cell-released cytokines producing an adaptive, resource conserving, behavioral response. While at an early stage, our findings further implicate immune system dysregulation as a mechanism in the development of psychosis.</div></div><div class="c-scholworks__media"><ul class="c-medialist"></ul></div></div><div class="c-scholworks__ancillary"><a class="c-scholworks__thumbnail" href="/uc/item/85g271k0"><img src="/cms-assets/c1a89740f2be8244d329319dacf0a575e667c9389e3af373246e3e12cef8f5c8" alt="Cover page: 39.1 DNA METHYLATION OF IMMUNE CELLS IN PERSONS AT CLINICAL HIGH RISK FOR PSYCHOSIS"/></a></div></section><section class="c-scholworks"><div class="c-scholworks__main-column"><ul class="c-scholworks__tag-list"><li class="c-scholworks__tag-article">Article</li><li class="c-scholworks__tag-peer">Peer Reviewed</li></ul><div><h3 class="c-scholworks__heading"><a href="/uc/item/5666t6qw"><div class="c-clientmarkup">SU127. Negative Symptoms in Youth at Clinical High Risk of Psychosis</div></a></h3></div><div class="c-authorlist"><ul class="c-authorlist__list"><li class="c-authorlist__begin"><a href="/search/?q=author%3ADevoe%2C%20Daniel">Devoe, Daniel</a>; </li><li><a href="/search/?q=author%3ACadenhead%2C%20Kristen">Cadenhead, Kristen</a>; </li><li><a href="/search/?q=author%3ACannon%2C%20Tyrone">Cannon, Tyrone</a>; </li><li><a href="/search/?q=author%3ACornblatt%2C%20Barbara">Cornblatt, Barbara</a>; </li><li><a href="/search/?q=author%3AMcGlashan%2C%20Tom">McGlashan, Tom</a>; </li><li><a href="/search/?q=author%3APerkins%2C%20Diana">Perkins, Diana</a>; </li><li><a href="/search/?q=author%3ASeidman%2C%20Larry%20J">Seidman, Larry J</a>; </li><li><a href="/search/?q=author%3ATsuang%2C%20Ming">Tsuang, Ming</a>; </li><li><a href="/search/?q=author%3AWalker%2C%20Elaine">Walker, Elaine</a>; </li><li><a href="/search/?q=author%3AWoods%2C%20Scott">Woods, Scott</a>; </li><li><a href="/search/?q=author%3ABearden%2C%20Carrie">Bearden, Carrie</a>; </li><li><a href="/search/?q=author%3AMathalon%2C%20Daniel">Mathalon, Daniel</a>; </li><li class="c-authorlist__end"><a href="/search/?q=author%3AAddington%2C%20Jean">Addington, Jean</a> </li></ul></div><div class="c-scholworks__publication"><a href="/uc/ucsd_postprints">UC San Diego Previously Published Works</a> (<!-- -->2017<!-- -->)</div><div class="c-scholworks__abstract"><div class="c-clientmarkup">Abstract Background: Longitudinal studies examining youth at clinical high risk (CHR) of psychosis have predominantly focused on positive symptoms. However, youth at CHR often demonstrate persistent and significant negative symptoms, which have been reported to be predictive of conversion to psychosis. The goal of this study was to examine negative symptoms over time in youth at CHR of psychosis and compare baseline negative symptoms in those who convert to psychosis with those who did not convert. Methods: Youth at CHR (N = 764) were recruited for the North American Prodrome Longitudinal Study (NAPLS 2) at 8 sites across North America. Negative symptoms were rated on the Scale of Prodromal Symptoms (SOPS) at baseline, 6, 12, 18, and 24 months. Difference in prevalence of negative symptoms was assessed using Z test and change in negative symptom severity over time was assessed using repeated measures analysis of variance ANOVA. Wilcoxon rank sum test and 2-sample t test were utilized to compare baseline negative symptoms in converters vs nonconverters. Results: The mean total negative symptom score at baseline was 11.90 (SD = 9.80). A majority of participants (84.57%) had at least one negative symptom rated ≥3 at baseline. Negative symptom severity significantly decreased over time compared to baseline measures. Eighty-six participants converted in total. In participants with at least one negative symptom of moderate severity or above (N ≥ 3), nonconverters had lower severity ratings on expression of emotion (M = 1.49, SD = 1.47 vs M = 1.94, SD = 1.64, P = .02) and ideational richness (M = 1.23, SD = 1.37 vs M = 1.60, SD = 1.35, P = .04) compared to converters at baseline. In participants who completed 24 months of assessment and had negative symptom severity of moderate severity or above (N ≥ 3), nonconverters had significantly better expression of emotion (M = 1.40, SD = 1.51) compared to converters (M = 1.79, SD = 1.63, P = .03). Conclusion: First, this study demonstrated that the majority of youth at CHR have moderate to severe negative symptoms at baseline. Second, both decreased expression of emotion and decreased ideational richness was significantly more severe in participants who converted and may be indicative of later conversion to psychosis. Thus, early and persistent higher negative symptom scores may represent subsequent risk of conversion to psychosis.</div></div><div class="c-scholworks__media"><ul class="c-medialist"></ul></div></div><div class="c-scholworks__ancillary"><a class="c-scholworks__thumbnail" href="/uc/item/5666t6qw"><img src="/cms-assets/4f75c4f2a44c9ede1a107b6e4d80f3a743cf5fc75d85f50da3598a9ef7e70728" alt="Cover page: SU127. Negative Symptoms in Youth at Clinical High Risk of Psychosis"/></a></div></section><section class="c-scholworks"><div class="c-scholworks__main-column"><ul class="c-scholworks__tag-list"><li class="c-scholworks__tag-article">Article</li><li class="c-scholworks__tag-peer">Peer Reviewed</li></ul><div><h3 class="c-scholworks__heading"><a href="/uc/item/5jd2p259"><div class="c-clientmarkup">23. Omega-3 Fatty Acid Versus Placebo in a Clinical High-Risk Sample From the North American Prodrome Longitudinal Studies (NAPLS) Consortium</div></a></h3></div><div class="c-authorlist"><ul class="c-authorlist__list"><li class="c-authorlist__begin"><a href="/search/?q=author%3ACadenhead%2C%20Kristin">Cadenhead, Kristin</a>; </li><li><a href="/search/?q=author%3AAddington%2C%20Jean">Addington, Jean</a>; </li><li><a href="/search/?q=author%3ACannon%2C%20Tyrone">Cannon, Tyrone</a>; </li><li><a href="/search/?q=author%3ACornblatt%2C%20Barbara">Cornblatt, Barbara</a>; </li><li><a href="/search/?q=author%3AMathalon%2C%20Daniel">Mathalon, Daniel</a>; </li><li><a href="/search/?q=author%3AMcGlashan%2C%20Tom">McGlashan, Tom</a>; </li><li><a href="/search/?q=author%3APerkins%2C%20Diana">Perkins, Diana</a>; </li><li><a href="/search/?q=author%3ASeidman%2C%20Larry%20J">Seidman, Larry J</a>; </li><li><a href="/search/?q=author%3ATsuang%2C%20Ming">Tsuang, Ming</a>; </li><li><a href="/search/?q=author%3AWalker%2C%20Elaine">Walker, Elaine</a>; </li><li class="c-authorlist__end"><a href="/search/?q=author%3AWoods%2C%20Scott">Woods, Scott</a> </li></ul></div><div class="c-scholworks__publication"><a href="/uc/ucsd_postprints">UC San Diego Previously Published Works</a> (<!-- -->2017<!-- -->)</div><div class="c-scholworks__abstract"><div class="c-clientmarkup">Abstract Background: Omega-3 Fatty Acids (FAs), EPA (eicosapentaenoic acid) and DHA (Docosahexaenoic acid), are essential for normal brain development and may also have neuroprotective properties. Dietary supplementation of EPA and DHA has beneficial effects in medical illnesses as well as depression, bipolar disorder, and dementia. Abnormal FA metabolism may play a role in the etiology of psychiatric illness. Studies of erythrocytes and skin fibroblasts have shown reduced levels of FAs and phospholipids in schizophrenia. Studies of Omega-3FA supplementation in schizophrenia have been mixed. Amminger et al performed a randomized, double-blind, placebo-controlled trial in 81 subjects with prodromal symptoms of psychosis. The treatment consisted of 1.2g/day of Omega-3FAs (700 mg EPA, 480 mg DHA). After 12 weeks, 2 (4.9%) of 41 individuals in the Omega-3FA group and 11 of 40 (27.5%) in the placebo group converted to a psychotic disorder. Omega-3FAs also significantly reduced symptoms and improved functioning. The Aims of the current study were to replicate the Amminger study in Clinical High Risk (CHR) subjects from the NAPLS consortium. Methods: This was a 24-week, randomized, double-blind, placebo, fixed dose-controlled study of Omega-3FA versus placebo in 127 CHR subjects. The Omega-3FA compound contained a 2:1 proportion of EPA to DHA. The total dose was 740 mg of EPA and 400 mg of DHA. Baseline diet characterization was assessed using a systematic checklist that includes Omega-3FA foods. In addition, fasting erythrocyte FA composition was assessed. Results: Of the 127 CHR subjects recruited into the trial, 118 completed baseline assessment, and 70 (59%) completed the 6-month trial. Seven (10% Kaplan-Meier) subjects converted to psychosis during the 24 months. The rate of psychotic conversion did not differ in the Omega-3FA (13%) versus Placebo (8%) samples. Conversion to psychosis was predicted by low Omega-3FA rich foods in the diet (Wald Statistic = 4.96, P < .05). Although there were significant improvements in symptom and functioning over time in Mixed Model analyses, there were no significant group or Group × Time interaction effects. Conclusion: The rate of conversion to psychosis in the present sample was lower than is typically observed in an at-risk population. Given the study attrition and low rate of conversion to psychosis, the trial was underpowered to replicate the conversion effect in the Amminger et al.’s study. Despite the overall improvement in symptoms and functioning over time in all subjects, there was no clear evidence of a differential effect in the sample on Omega-3FA vs Placebo. Further work is needed to better tease out the role of diet and Omega-3FA in mental illness. The finding of a significant association between baseline diet low in Omega-3FA rich foods and later conversion to psychosis raises the question of whether it is possible to influence both physical and mental health with lifestyle choices including diet.</div></div><div class="c-scholworks__media"><ul class="c-medialist"></ul></div></div><div class="c-scholworks__ancillary"><a class="c-scholworks__thumbnail" href="/uc/item/5jd2p259"><img src="/cms-assets/0d42bcaf8ad048fd0ee8123a8d5b3da501aedef669a69070369b824d8ac3e8d9" alt="Cover page: 23. Omega-3 Fatty Acid Versus Placebo in a Clinical High-Risk Sample From the North American Prodrome Longitudinal Studies (NAPLS) Consortium"/></a></div></section><section class="c-scholworks"><div class="c-scholworks__main-column"><ul class="c-scholworks__tag-list"><li class="c-scholworks__tag-article">Article</li><li class="c-scholworks__tag-peer">Peer Reviewed</li></ul><div><h3 class="c-scholworks__heading"><a href="/uc/item/53534296"><div class="c-clientmarkup">24.2 NEUROCOGNITIVE PROFILES IN THE PRODROME TO PSYCHOSIS IN NAPLS-1</div></a></h3></div><div class="c-authorlist"><ul class="c-authorlist__list"><li class="c-authorlist__begin"><a href="/search/?q=author%3AVelthorst%2C%20Eva">Velthorst, Eva</a>; </li><li><a href="/search/?q=author%3ABearden%2C%20Carrie">Bearden, Carrie</a>; </li><li><a href="/search/?q=author%3AMeyer%2C%20Eric">Meyer, Eric</a>; </li><li><a href="/search/?q=author%3AGiuliano%2C%20Anthony">Giuliano, Anthony</a>; </li><li><a href="/search/?q=author%3AAddington%2C%20Jean">Addington, Jean</a>; </li><li><a href="/search/?q=author%3ACadenhead%2C%20Kristin">Cadenhead, Kristin</a>; </li><li><a href="/search/?q=author%3ACannon%2C%20Tyrone">Cannon, Tyrone</a>; </li><li><a href="/search/?q=author%3ACornblatt%2C%20Barbara">Cornblatt, Barbara</a>; </li><li><a href="/search/?q=author%3AMcglashan%2C%20Thomas">Mcglashan, Thomas</a>; </li><li><a href="/search/?q=author%3APerkins%2C%20Diana">Perkins, Diana</a>; </li><li><a href="/search/?q=author%3ATsuang%2C%20Ming">Tsuang, Ming</a>; </li><li><a href="/search/?q=author%3AWalker%2C%20Elaine">Walker, Elaine</a>; </li><li><a href="/search/?q=author%3AWoods%2C%20Scott">Woods, Scott</a>; </li><li class="c-authorlist__end"><a href="/search/?q=author%3ASeidman%2C%20Larry">Seidman, Larry</a> </li></ul></div><div class="c-scholworks__publication"><a href="/uc/ucsd_postprints">UC San Diego Previously Published Works</a> (<!-- -->2018<!-- -->)</div><div class="c-scholworks__abstract"><div class="c-clientmarkup">Abstract <h3>Background</h3> The vast majority of studies of neuropsychological (NP) functioning in Clinical High Risk (CHR) cohorts have examined group averages, possibly concealing a range of subgroups ranging from very impaired to high functioning. Our objective was to assess NP profiles and to explore associations with conversion to psychosis, functional and diagnostic outcome. <h3>Methods</h3> Data were acquired from 324 participants (mean age 18.4) in the first phase of the North American Prodrome Longitudinal Study (NAPLS-1), a multi-site consortium following individuals for up to 2½ years. We applied Ward’s method for hierarchical clustering data to 8 baseline neurocognitive measures, in 166 CHR individuals, 49 non-CHR youth with a family history of psychosis, and 109 healthy controls. We tested whether cluster membership was associated with conversion to psychosis, social and role functioning, and follow-up diagnosis. Analyses were repeated after data were clustered based on independently developed clinical decision rules. <h3>Results</h3> Four neurocognitive clusters were identified: Significantly Impaired (n=33); Mildly Impaired (n=82); Normal (n=145) and High (n=64). The Significantly Impaired subgroup demonstrated the largest deviations on processing speed and memory tasks and had a conversion rate of 58%, a 40% chance of developing a schizophrenia spectrum diagnosis (compared to 24.4% in the Mildly Impaired, and 10.3% in the other two groups combined), and significantly worse functioning at baseline and 12-months. Data clustered using clinical decision rules yielded similar results, pointing to high convergent validity. <h3>Discussion</h3> Despite extensive neuropsychological investigations within CHR cohorts, this is one of the first studies to investigate NP clustering profiles as a contributor to heterogeneity in outcome. Our results indicate that the four NP profiles vary substantially in their outcome, underscoring the relevance of cognitive functioning in the prediction of illness progression. Our findings tentatively suggest that individualized cognitive profiling should be explored in clinical settings.</div></div><div class="c-scholworks__media"><ul class="c-medialist"></ul></div></div><div class="c-scholworks__ancillary"><a class="c-scholworks__thumbnail" href="/uc/item/53534296"><img src="/cms-assets/657a3125df11cbcd556b3cf3a95485228ac64c40f2e47acd76e6f7fad3d1c789" alt="Cover page: 24.2 NEUROCOGNITIVE PROFILES IN THE PRODROME TO PSYCHOSIS IN NAPLS-1"/></a></div></section><section class="c-scholworks"><div class="c-scholworks__main-column"><ul class="c-scholworks__tag-list"><li class="c-scholworks__tag-article">Article</li><li class="c-scholworks__tag-peer">Peer Reviewed</li></ul><div><h3 class="c-scholworks__heading"><a href="/uc/item/0t23x1cq"><div class="c-clientmarkup">59.4 Networks of Blood Analytes are Collectively Informative of Risk of Conversion to Schizophrenia</div></a></h3></div><div class="c-authorlist"><ul class="c-authorlist__list"><li class="c-authorlist__begin"><a href="/search/?q=author%3AJeffries%2C%20Clark">Jeffries, Clark</a>; </li><li><a href="/search/?q=author%3APerkins%2C%20Diana">Perkins, Diana</a>; </li><li><a href="/search/?q=author%3AAddington%2C%20Jean">Addington, Jean</a>; </li><li><a href="/search/?q=author%3ABearden%2C%20Carrie">Bearden, Carrie</a>; </li><li><a href="/search/?q=author%3ACadenhead%2C%20Kristen">Cadenhead, Kristen</a>; </li><li><a href="/search/?q=author%3ACannon%2C%20Tyrone">Cannon, Tyrone</a>; </li><li><a href="/search/?q=author%3ACornblatt%2C%20Barbara">Cornblatt, Barbara</a>; </li><li><a href="/search/?q=author%3AMathalon%2C%20Daniel">Mathalon, Daniel</a>; </li><li><a href="/search/?q=author%3AMcGlashan%2C%20Tom">McGlashan, Tom</a>; </li><li><a href="/search/?q=author%3ASeidman%2C%20Larry%20J">Seidman, Larry J</a>; </li><li><a href="/search/?q=author%3ATsuang%2C%20Ming">Tsuang, Ming</a>; </li><li><a href="/search/?q=author%3AWalker%2C%20Elaine">Walker, Elaine</a>; </li><li class="c-authorlist__end"><a href="/search/?q=author%3AWoods%2C%20Scott">Woods, Scott</a> </li></ul></div><div class="c-scholworks__publication"><a href="/uc/ucsd_postprints">UC San Diego Previously Published Works</a> (<!-- -->2017<!-- -->)</div><div class="c-scholworks__abstract"><div class="c-clientmarkup">Abstract Background: The presence and severity of attenuated-psychosis symptoms define a clinical high risk (CHR) population at elevated risk for psychotic disorders. The NAPLS project is a prospective study of mechanisms contributing to psychosis vulnerability in persons at CHR. Here we investigated a hypothesized role for the highly-integrated immune and redox systems in the development of psychosis. Methods: We examined expression of 143 plasma analytes from a subgroup of the NAPLS2 cohort, including 32 CHR with subsequent psychosis conversion, 40 CHR followed for 2 years without psychosis, and 35 unaffected subjects. We used a Luminex platform with analytes chosen to reflect immune, redox, hormonal, and metabolic system status, including many analytes previously associated with schizophrenia and psychosis risk. We applied correlation network analysis to discover potentially co-regulated networks associated with later development of psychosis. Results: Several robust (r > .75) and highly significant (P < .0001 after correction for multiple testing) correlation networks were found in all groups, including a network involving IL3, IL5, IL7, and IL13, and a network involving CCL5, BDNF, TSH, and PDGF. There were significantly fewer nodes in CHR-converters compared with CHR-nonconverters and unaffected subjects. In unaffected subjects, plasminogen activator inhibitor-1 (PAI-1) was highly correlated with matrix metallopeptidases (MMP) 7, 9 and 10 and CD40LG, this network was absent in CHR subjects, and in CHR-converters PAI-1 was robustly and significantly correlated with TIMP1, CCL13, and TIMP1. Conclusion: A pattern of robust and highly significant correlation networks in plasma analytes suggests shared regulatory mechanisms for the inter-correlated analytes. The lower number of correlated analytes in CHR subjects who converted to psychosis suggest a shift in regulation, as does the change in the correlation network involving PAI-1. PAI-1 is of interest given studies linking schizophrenia with reduced tissue plasminogen activator (tPA) and increases in negative regulators of tPA, including activation of both PAI-1and TIMP1 with oxidative stress. In addition, a recent study links toxoplasmosis infection and schizophrenia risk to a pathway involving PAI-1 and TIMP1. Patricio O’Donnell, Pfizer Inc.</div></div><div class="c-scholworks__media"><ul class="c-medialist"></ul></div></div><div class="c-scholworks__ancillary"><a class="c-scholworks__thumbnail" href="/uc/item/0t23x1cq"><img src="/cms-assets/d7f57468db9e0db827d0c1e60b1022a1c2a6b060ce52f3cb5f499b566cb43147" alt="Cover page: 59.4 Networks of Blood Analytes are Collectively Informative of Risk of Conversion to Schizophrenia"/></a></div></section><section class="c-scholworks"><div class="c-scholworks__main-column"><ul class="c-scholworks__tag-list"><li class="c-scholworks__tag-article">Article</li><li class="c-scholworks__tag-peer">Peer Reviewed</li></ul><div><h3 class="c-scholworks__heading"><a href="/uc/item/9cb1z9c2"><div class="c-clientmarkup">Common Data Elements for National Institute of Mental Health–Funded Translational Early Psychosis Research</div></a></h3></div><div class="c-authorlist"><ul class="c-authorlist__list"><li class="c-authorlist__begin"><a href="/search/?q=author%3A%C3%96ng%C3%BCr%2C%20Dost">Öngür, Dost</a>; </li><li><a href="/search/?q=author%3ACarter%2C%20Cameron%20S">Carter, Cameron S</a>; </li><li><a href="/search/?q=author%3AGur%2C%20Raquel%20E">Gur, Raquel E</a>; </li><li><a href="/search/?q=author%3APerkins%2C%20Diana">Perkins, Diana</a>; </li><li><a href="/search/?q=author%3ASawa%2C%20Akira">Sawa, Akira</a>; </li><li><a href="/search/?q=author%3ASeidman%2C%20Larry%20J">Seidman, Larry J</a>; </li><li><a href="/search/?q=author%3ATamminga%2C%20Carol">Tamminga, Carol</a>; </li><li><a href="/search/?q=author%3AHuggins%2C%20Wayne">Huggins, Wayne</a>; </li><li class="c-authorlist__end"><a href="/search/?q=author%3AHamilton%2C%20Carol">Hamilton, Carol</a> </li></ul></div><div class="c-scholworks__publication"><a href="/uc/ucd_postprints">UC Davis Previously Published Works</a> (<!-- -->2020<!-- -->)</div><div class="c-scholworks__abstract"><div class="c-clientmarkup">The National Institutes of Health has established the PhenX Toolkit as a web-based resource containing consensus measures freely available to the research community. The National Institute of Mental Health (NIMH) has introduced the Mental Health Research Core Collection as part of the PhenX Toolkit and recently convened the PhenX Early Psychosis Working Group to generate the PhenX Early Psychosis Specialty Collection. The Working Group consisted of two complementary panels for clinical and translational research. We review the process, deliberations, and products of the translational research panel. The Early Psychosis Specialty Collection rationale for measure selection as well as additional information and protocols for obtaining each measure are available on the PhenX website (https://www.phenxtoolkit.org). The NIMH strongly encourages investigators to use instruments from the PhenX Mental Health Research Collections in NIMH-funded studies and discourages use of alternative measures to collect similar data without justification. We also discuss some of the potential advances that can be achieved by collecting common data elements across large-scale longitudinal studies of early psychosis.</div></div><div class="c-scholworks__media"><ul class="c-medialist"></ul></div></div><div class="c-scholworks__ancillary"><a class="c-scholworks__thumbnail" href="/uc/item/9cb1z9c2"><img src="/cms-assets/18d1d24010d51f47cde8ae6a9e9eee3b6453f481299583d9a4f2f6003cdc6777" alt="Cover page: Common Data Elements for National Institute of Mental Health–Funded Translational Early Psychosis Research"/></a></div></section><section class="c-scholworks"><div class="c-scholworks__main-column"><ul class="c-scholworks__tag-list"><li class="c-scholworks__tag-article">Article</li><li class="c-scholworks__tag-peer">Peer Reviewed</li></ul><div><h3 class="c-scholworks__heading"><a href="/uc/item/8j42s24m"><div class="c-clientmarkup">Sex- and Age-Specific Deviations in Cerebellar Structure and Their Link With Symptom Dimensions and Clinical Outcome in Individuals at Clinical High Risk for Psychosis.</div></a></h3></div><div class="c-authorlist"><ul class="c-authorlist__list"><li class="c-authorlist__begin"><a href="/search/?q=author%3AWoods%2C%20Scott">Woods, Scott</a>; </li><li><a href="/search/?q=author%3ACannon%2C%20Tyrone">Cannon, Tyrone</a>; </li><li><a href="/search/?q=author%3AWalker%2C%20Elaine">Walker, Elaine</a>; </li><li><a href="/search/?q=author%3ASefik%2C%20Esra">Sefik, Esra</a>; </li><li><a href="/search/?q=author%3ABoamah%2C%20Michelle">Boamah, Michelle</a>; </li><li><a href="/search/?q=author%3AAddington%2C%20Jean">Addington, Jean</a>; </li><li><a href="/search/?q=author%3ACornblatt%2C%20Barbara">Cornblatt, Barbara</a>; </li><li><a href="/search/?q=author%3AKeshavan%2C%20Matcheri">Keshavan, Matcheri</a>; </li><li><a href="/search/?q=author%3APerkins%2C%20Diana">Perkins, Diana</a>; </li><li><a href="/search/?q=author%3AStone%2C%20William">Stone, William</a>; </li><li><a href="/search/?q=author%3AMathalon%2C%20Daniel">Mathalon, Daniel</a>; </li><li><a href="/search/?q=author%3ABearden%2C%20Carrie">Bearden, Carrie</a>; </li><li><a href="/search/?q=author%3ACadenhead%2C%20Kristin">Cadenhead, Kristin</a>; </li><li class="c-authorlist__end"><a href="/search/?q=author%3ATsuang%2C%20Ming">Tsuang, Ming</a> </li></ul></div><div class="c-scholworks__publication"><a href="/uc/ucsf_postprints">UC San Francisco Previously Published Works</a> (<!-- -->2023<!-- -->)</div><div class="c-scholworks__abstract"><div class="c-clientmarkup">BACKGROUND: The clinical high-risk (CHR) period offers a temporal window into neurobiological deviations preceding psychosis onset, but little attention has been given to regions outside the cerebrum in large-scale studies of CHR. Recently, the North American Prodrome Longitudinal Study (NAPLS)-2 revealed altered functional connectivity of the cerebello-thalamo-cortical circuitry among individuals at CHR; however, cerebellar morphology remains underinvestigated in this at-risk population, despite growing evidence of its involvement in psychosis. STUDY DESIGN: In this multisite study, we analyzed T1-weighted magnetic resonance imaging scans obtained from N = 469 CHR individuals (61% male, ages = 12-36 years) and N = 212 healthy controls (52% male, ages = 12-34 years) from NAPLS-2, with a focus on cerebellar cortex and white matter volumes separately. Symptoms were rated by the Structured Interview for Psychosis-Risk Syndromes (SIPS). The outcome by two-year follow-up was categorized as in-remission, symptomatic, prodromal-progression, or psychotic. General linear models were used for case-control comparisons and tests for volumetric associations with baseline SIPS ratings and clinical outcomes. STUDY RESULTS: Cerebellar cortex and white matter volumes differed between the CHR and healthy control groups at baseline, with sex moderating the difference in cortical volumes, and both sex and age moderating the difference in white matter volumes. Baseline ratings for major psychosis-risk dimensions as well as a clinical outcome at follow-up had tissue-specific associations with cerebellar volumes. CONCLUSIONS: These findings point to clinically relevant deviations in cerebellar cortex and white matter structures among CHR individuals and highlight the importance of considering the complex interplay between sex and age when studying the neuromaturational substrates of psychosis risk.</div></div><div class="c-scholworks__media"><ul class="c-medialist"></ul></div></div><div class="c-scholworks__ancillary"><a class="c-scholworks__thumbnail" href="/uc/item/8j42s24m"><img src="/cms-assets/f05a725d546a91e264392937a9ba4ff55f91b236eaa802323956c51ac63ed7d0" alt="Cover page: Sex- and Age-Specific Deviations in Cerebellar Structure and Their Link With Symptom Dimensions and Clinical Outcome in Individuals at Clinical High Risk for Psychosis."/></a></div></section><section class="c-scholworks"><div class="c-scholworks__main-column"><ul class="c-scholworks__tag-list"><li class="c-scholworks__tag-article">Article</li><li class="c-scholworks__tag-peer">Peer Reviewed</li></ul><div><h3 class="c-scholworks__heading"><a href="/uc/item/93m2x62j"><div class="c-clientmarkup">T116. PREDICTION OF REMISSION IN NON-CONVERTING INDIVIDUALS AT CLINICAL HIGH RISK FOR PSYCHOSIS</div></a></h3></div><div class="c-authorlist"><ul class="c-authorlist__list"><li class="c-authorlist__begin"><a href="/search/?q=author%3AWorthington%2C%20Michelle">Worthington, Michelle</a>; </li><li><a href="/search/?q=author%3AAddington%2C%20Jean">Addington, Jean</a>; </li><li><a href="/search/?q=author%3ABearden%2C%20Carrie">Bearden, Carrie</a>; </li><li><a href="/search/?q=author%3ACadenhead%2C%20Kristin">Cadenhead, Kristin</a>; </li><li><a href="/search/?q=author%3ACornblatt%2C%20Barbara">Cornblatt, Barbara</a>; </li><li><a href="/search/?q=author%3AMathalon%2C%20Daniel">Mathalon, Daniel</a>; </li><li><a href="/search/?q=author%3AMcGlashan%2C%20Thomas">McGlashan, Thomas</a>; </li><li><a href="/search/?q=author%3APerkins%2C%20Diana">Perkins, Diana</a>; </li><li><a href="/search/?q=author%3ASeidman%2C%20Larry">Seidman, Larry</a>; </li><li><a href="/search/?q=author%3ATsuang%2C%20Ming">Tsuang, Ming</a>; </li><li><a href="/search/?q=author%3AWalker%2C%20Elaine">Walker, Elaine</a>; </li><li><a href="/search/?q=author%3AWoods%2C%20Scott">Woods, Scott</a>; </li><li class="c-authorlist__end"><a href="/search/?q=author%3ACannon%2C%20Tyrone">Cannon, Tyrone</a> </li></ul></div><div class="c-scholworks__publication"><a href="/uc/ucsd_postprints">UC San Diego Previously Published Works</a> (<!-- -->2020<!-- -->)</div><div class="c-scholworks__abstract"><div class="c-clientmarkup">Abstract <h3>Background</h3> The clinical high-risk period before a first episode of psychosis (CHR-P) has been widely studied in the past 30 years with the goal of understanding the development of psychosis. Despite the progress in understanding what factors are associated with conversion to psychosis from the CHR-P state, less attention has been paid to the individuals who do not transition to psychosis. It is estimated that approximately 75–80% of individuals do not go on to convert to psychosis from the CHR-P state and this group should not simply be characterized as the inverse of conversion. To date, only a handful of studies have examined the characteristics and predictors of those who do not convert to psychosis and ultimately either remit or continue to meet symptom-based CHR-P criteria. The present study took an exploratory empirical approach to determining potential factors that predict remission in non-converters. <h3>Methods</h3> Participants were drawn from the North American Prodrome Longitudinal Study (NAPLS2). Univariate Kaplan Meier survival analyses were performed on a pool of available demographic and clinical variables. Variables that were significant (p < 0.05) in the univariate analyses were then included in a multivariate Cox proportional hazard regression to predict remission. Remission was defined as all SOPS positive symptom subscale items rated as a 2 or lower at any given follow-up visit. <h3>Results</h3> A total of 359 participants from the NAPLS2 study who did not convert to psychosis and had data for at least the baseline and first follow-up visit and were included in this study. Of these participants, 174 met criteria for symptomatic remission. A total of 57 clinical variables were tested in univariate analyses and 14 of these variables met criteria for inclusion in the multivariate model. The variables included in the multivariate model were demographic variables (ethnicity, stressful life events), items from the Scale of Prodromal Symptoms (SOPS) (avolition, dysphoric mood), subtest scores from the MATRICS Cognitive Battery (speed of processing, verbal learning, verbal and non-verbal working memory, reasoning and problem solving, visual learning), one item from the Calgary Depression Scale for Schizophrenia (CDSS) (pathological guilt) and measures of functioning (GAF decline in past year, lowest GAF score in the past year). Overall, the multivariate model achieved a C-index of 0.64 (SE = 0.02) and p-value of 0.001 in predicting remission. In the multivariate model, significant covariates included stressful life events (HR = .95, p = .006), Hispanic ethnicity (HR = 1.45, p = .045), and avolition (HR = .89, p = .04). Covariates approaching significance included visual learning (HR = 1.02, p = .07), and GAF decline in the past year (HR = 1.01, p = .09). <h3>Discussion</h3> This study is the first to use a data-driven approach to systematically assess clinical and demographic predictors of symptomatic remission in individuals who do not convert to psychosis. The identified set of significant clinical variables is novel, suggesting that remission represents a unique clinical phenomenon and suggesting that further study is warranted to best understand factors contributing to resilience and recovery from the CHR-P period.</div></div><div class="c-scholworks__media"><ul class="c-medialist"></ul></div></div><div class="c-scholworks__ancillary"><a class="c-scholworks__thumbnail" href="/uc/item/93m2x62j"><img src="/cms-assets/dc5330705c0284aba97b14187054fe8793f35faf9fe378706165514a92dfa495" alt="Cover page: T116. PREDICTION OF REMISSION IN NON-CONVERTING INDIVIDUALS AT CLINICAL HIGH RISK FOR PSYCHOSIS"/></a></div></section><section class="c-scholworks"><div class="c-scholworks__main-column"><ul class="c-scholworks__tag-list"><li class="c-scholworks__tag-article">Article</li><li class="c-scholworks__tag-peer">Peer Reviewed</li></ul><div><h3 class="c-scholworks__heading"><a href="/uc/item/3qn67694"><div class="c-clientmarkup">S244. CHARACTERIZING OUTCOMES OF CLINICAL HIGH-RISK NON-CONVERTERS USING GROUP-BASED TRAJECTORY MODELING</div></a></h3></div><div class="c-authorlist"><ul class="c-authorlist__list"><li class="c-authorlist__begin"><a href="/search/?q=author%3AAllswede%2C%20Dana">Allswede, Dana</a>; </li><li><a href="/search/?q=author%3ACannon%2C%20Tyrone">Cannon, Tyrone</a>; </li><li><a href="/search/?q=author%3AAddington%2C%20Jean">Addington, Jean</a>; </li><li><a href="/search/?q=author%3ABearden%2C%20Carrie">Bearden, Carrie</a>; </li><li><a href="/search/?q=author%3ACadenhead%2C%20Kristin">Cadenhead, Kristin</a>; </li><li><a href="/search/?q=author%3ACornblatt%2C%20Barbara">Cornblatt, Barbara</a>; </li><li><a href="/search/?q=author%3AMathalon%2C%20Daniel">Mathalon, Daniel</a>; </li><li><a href="/search/?q=author%3AThomas%2C%20McGlashan">Thomas, McGlashan</a>; </li><li><a href="/search/?q=author%3APerkins%2C%20Diana">Perkins, Diana</a>; </li><li><a href="/search/?q=author%3ASeidman%2C%20Larry">Seidman, Larry</a>; </li><li><a href="/search/?q=author%3ATsuang%2C%20Ming">Tsuang, Ming</a>; </li><li><a href="/search/?q=author%3AWalker%2C%20Elaine">Walker, Elaine</a>; </li><li class="c-authorlist__end"><a href="/search/?q=author%3AWoods%2C%20Scott">Woods, Scott</a> </li></ul></div><div class="c-scholworks__publication"><a href="/uc/ucsd_postprints">UC San Diego Previously Published Works</a> (<!-- -->2018<!-- -->)</div><div class="c-scholworks__abstract"><div class="c-clientmarkup">Abstract <h3>Background</h3> The development of the clinical high-risk (CHR) prodromal criteria has facilitated advancement in understanding conversion to psychosis and has provided opportunities for early intervention and treatment for these individuals. However, the majority of CHR cases do not meet full criteria for conversion, yet continue to experience clinically significant symptoms and impairment in daily functioning. It is likely that many of these individuals would also benefit from additional intervention and treatment, but the outcomes and needs of these “non-converters” are not well characterized. Identifying common longitudinal patterns of symptoms and functioning of non-converters would support the identification of individuals who continue to require treatment and tailoring of services to their specific needs. <h3>Methods</h3> We used group-based trajectory modeling to identify common longitudinal symptom and functioning trajectories among CHR cases (N=561) in the second phase of the North American Prodrome Longitudinal Study (NAPLS2). Covariant trajectories of symptoms (including positive, negative, disorganized, and general) and functioning (including role and social) were examined. Models were tested for replicability in an independent sample of CHR cases (N=291) from the first phase of NAPLS (NAPLS1). <h3>Results</h3> We identified a subgroup of individuals who exhibited symptom remission and functioning within the normal range, as well as at least two additional subgroups that exhibited different patterns of ongoing, clinically significant symptoms and functional deficits. <h3>Discussion</h3> We are currently investigating the validity of these subgroups by assessing their association with a variety of risk factors and biomarkers.</div></div><div class="c-scholworks__media"><ul class="c-medialist"></ul></div></div><div class="c-scholworks__ancillary"><a class="c-scholworks__thumbnail" href="/uc/item/3qn67694"><img src="/cms-assets/91f5493df01c833748ff81171223dc3aaddff5f5cb4c273ec53d8300366ba731" alt="Cover page: S244. CHARACTERIZING OUTCOMES OF CLINICAL HIGH-RISK NON-CONVERTERS USING GROUP-BASED TRAJECTORY MODELING"/></a></div></section><section class="c-scholworks"><div class="c-scholworks__main-column"><ul class="c-scholworks__tag-list"><li class="c-scholworks__tag-article">Article</li><li class="c-scholworks__tag-peer">Peer Reviewed</li></ul><div><h3 class="c-scholworks__heading"><a href="/uc/item/160961tz"><div class="c-clientmarkup">SU127. Negative Symptoms in Youth at Clinical High Risk of Psychosis</div></a></h3></div><div class="c-authorlist"><ul class="c-authorlist__list"><li class="c-authorlist__begin"><a href="/search/?q=author%3ADevoe%2C%20Daniel">Devoe, Daniel</a>; </li><li><a href="/search/?q=author%3ACadenhead%2C%20Kristen">Cadenhead, Kristen</a>; </li><li><a href="/search/?q=author%3ACannon%2C%20Tyrone">Cannon, Tyrone</a>; </li><li><a href="/search/?q=author%3ACornblatt%2C%20Barbara">Cornblatt, Barbara</a>; </li><li><a href="/search/?q=author%3AMcGlashan%2C%20Tom">McGlashan, Tom</a>; </li><li><a href="/search/?q=author%3APerkins%2C%20Diana">Perkins, Diana</a>; </li><li><a href="/search/?q=author%3ASeidman%2C%20Larry%20J">Seidman, Larry J</a>; </li><li><a href="/search/?q=author%3ATsuang%2C%20Ming">Tsuang, Ming</a>; </li><li><a href="/search/?q=author%3AWalker%2C%20Elaine">Walker, Elaine</a>; </li><li><a href="/search/?q=author%3AWoods%2C%20Scott">Woods, Scott</a>; </li><li><a href="/search/?q=author%3ABearden%2C%20Carrie">Bearden, Carrie</a>; </li><li><a href="/search/?q=author%3AMathalon%2C%20Daniel">Mathalon, Daniel</a>; </li><li class="c-authorlist__end"><a href="/search/?q=author%3AAddington%2C%20Jean">Addington, Jean</a> </li></ul></div><div class="c-scholworks__publication"><a href="/uc/ucsd_postprints">UC San Diego Previously Published Works</a> (<!-- -->2017<!-- -->)</div><div class="c-scholworks__abstract"><div class="c-clientmarkup">Abstract Background: Longitudinal studies examining youth at clinical high risk (CHR) of psychosis have predominantly focused on positive symptoms. However, youth at CHR often demonstrate persistent and significant negative symptoms, which have been reported to be predictive of conversion to psychosis. The goal of this study was to examine negative symptoms over time in youth at CHR of psychosis and compare baseline negative symptoms in those who convert to psychosis with those who did not convert. Methods: Youth at CHR (N = 764) were recruited for the North American Prodrome Longitudinal Study (NAPLS 2) at 8 sites across North America. Negative symptoms were rated on the Scale of Prodromal Symptoms (SOPS) at baseline, 6, 12, 18, and 24 months. Difference in prevalence of negative symptoms was assessed using Z test and change in negative symptom severity over time was assessed using repeated measures analysis of variance ANOVA. Wilcoxon rank sum test and 2-sample t test were utilized to compare baseline negative symptoms in converters vs nonconverters. Results: The mean total negative symptom score at baseline was 11.90 (SD = 9.80). A majority of participants (84.57%) had at least one negative symptom rated ≥3 at baseline. Negative symptom severity significantly decreased over time compared to baseline measures. Eighty-six participants converted in total. In participants with at least one negative symptom of moderate severity or above (N ≥ 3), nonconverters had lower severity ratings on expression of emotion (M = 1.49, SD = 1.47 vs M = 1.94, SD = 1.64, P = .02) and ideational richness (M = 1.23, SD = 1.37 vs M = 1.60, SD = 1.35, P = .04) compared to converters at baseline. In participants who completed 24 months of assessment and had negative symptom severity of moderate severity or above (N ≥ 3), nonconverters had significantly better expression of emotion (M = 1.40, SD = 1.51) compared to converters (M = 1.79, SD = 1.63, P = .03). Conclusion: First, this study demonstrated that the majority of youth at CHR have moderate to severe negative symptoms at baseline. Second, both decreased expression of emotion and decreased ideational richness was significantly more severe in participants who converted and may be indicative of later conversion to psychosis. Thus, early and persistent higher negative symptom scores may represent subsequent risk of conversion to psychosis.</div></div><div class="c-scholworks__media"><ul class="c-medialist"></ul></div></div><div class="c-scholworks__ancillary"><a class="c-scholworks__thumbnail" href="/uc/item/160961tz"><img src="/cms-assets/e6380432417ccd93c81ccffd3e1f75bf548098163e748c149cb817085c9de04c" alt="Cover page: SU127. Negative Symptoms in Youth at Clinical High Risk of Psychosis"/></a></div></section><nav class="c-pagination--next"><ul><li><a href="" aria-label="you are on result set 1" class="c-pagination__item--current">1</a></li><li><a href="" aria-label="go to result set 2" class="c-pagination__item">2</a></li><li><a href="" aria-label="go to result set 3" class="c-pagination__item">3</a></li><li><a href="" aria-label="go to result set 4" class="c-pagination__item">4</a></li><li><a href="" aria-label="go to result set 14" class="c-pagination__item">14</a></li><li class="c-pagination__next"><a href="" aria-label="go to Next result set">Next</a></li></ul></nav></section></main></form></div><div><div class="c-toplink"><a href="javascript:window.scrollTo(0, 0)">Top</a></div><footer class="c-footer"><nav class="c-footer__nav"><ul><li><a href="/">Home</a></li><li><a href="/aboutEschol">About eScholarship</a></li><li><a href="/campuses">Campus Sites</a></li><li><a href="/ucoapolicies">UC Open Access Policy</a></li><li><a href="/publishing">eScholarship Publishing</a></li><li><a href="https://www.cdlib.org/about/accessibility.html">Accessibility</a></li><li><a href="/privacypolicy">Privacy Statement</a></li><li><a href="/policies">Site Policies</a></li><li><a href="/terms">Terms of Use</a></li><li><a href="/login"><strong>Admin Login</strong></a></li><li><a href="https://help.escholarship.org"><strong>Help</strong></a></li></ul></nav><div class="c-footer__logo"><a href="/"><img class="c-lazyimage" data-src="/images/logo_footer-eschol.svg" alt="eScholarship, University of California"/></a></div><div class="c-footer__copyright">Powered by the<br/><a href="http://www.cdlib.org">California Digital Library</a><br/>Copyright © 2017<br/>The Regents of the University of California</div></footer></div></div></div></div> <script>window.jscholApp_initialPageData = {"header":{"campusID":"root","campusName":"eScholarship","ancestorID":null,"ancestorName":null,"campuses":[{"id":"","name":"eScholarship at..."},{"id":"ucb","name":"UC Berkeley"},{"id":"ucd","name":"UC Davis"},{"id":"uci","name":"UC Irvine"},{"id":"ucla","name":"UCLA"},{"id":"ucm","name":"UC Merced"},{"id":"ucr","name":"UC Riverside"},{"id":"ucsd","name":"UC San Diego"},{"id":"ucsf","name":"UCSF"},{"id":"ucsb","name":"UC Santa Barbara"},{"id":"ucsc","name":"UC Santa Cruz"},{"id":"ucop","name":"UC Office of the President"},{"id":"lbnl","name":"Lawrence Berkeley National Laboratory"},{"id":"anrcs","name":"UC Agriculture & Natural Resources"}],"logo":null,"bgColor":null,"elColor":null,"directSubmit":null,"directSubmitURL":null,"directManageURLauthor":null,"directManageURLeditor":null,"nav_bar":[{"id":1,"name":"About eScholarship","type":"folder","sub_nav":[{"id":5,"name":"About eScholarship","slug":"aboutEschol","type":"page","url":"/aboutEschol"},{"id":11,"name":"eScholarship Repository","slug":"repository","type":"page","url":"/repository"},{"id":28,"url":"/publishing","name":"eScholarship Publishing","type":"link"},{"id":29,"name":"Site policies","slug":"policies","type":"page","url":"/policies"},{"id":13,"name":"Terms of Use and Copyright Information","slug":"terms","type":"page","url":"/terms"},{"id":26,"name":"Coming soon","slug":"comingSoon","type":"page","hidden":true,"url":"/comingSoon"},{"id":27,"name":"Privacy statement","slug":"privacyPolicy","type":"page","url":"/privacyPolicy"}]},{"id":2,"name":"Campus Sites","type":"folder","sub_nav":[{"id":15,"url":"/uc/ucb","name":"UC Berkeley","type":"link"},{"id":16,"url":"/uc/ucd","name":"UC Davis","type":"link"},{"id":17,"url":"/uc/uci","name":"UC Irvine","type":"link"},{"id":6,"url":"/uc/ucla","name":"UCLA","type":"link"},{"id":18,"url":"/uc/ucm","name":"UC Merced","type":"link"},{"id":19,"url":"/uc/ucr","name":"UC Riverside","type":"link"},{"id":20,"url":"/uc/ucsd","name":"UC San Diego","type":"link"},{"id":9,"url":"/uc/ucsf","name":"UCSF","type":"link"},{"id":21,"url":"/uc/ucsb","name":"UC Santa Barbara","type":"link"},{"id":22,"url":"/uc/ucsc","name":"UC Santa Cruz","type":"link"},{"id":23,"url":"/uc/ucop","name":"UC Office of the President","type":"link"},{"id":24,"url":"/uc/lbnl","name":"Lawrence Berkeley National Laboratory","type":"link"},{"id":25,"url":"/uc/anrcs","name":"UC Agriculture & Natural Resources","type":"link"}]},{"id":10,"name":"UC Open Access Policies","slug":"ucoapolicies","type":"page","url":"/ucoapolicies"},{"id":12,"name":"eScholarship Publishing","slug":"publishing","type":"page","url":"/publishing"}],"social":{"facebook":null,"twitter":null,"rss":"/rss/unit/root"},"breadcrumb":[{"name":"eScholarship","id":"root","url":"/"}]},"campuses":[{"id":"","name":"eScholarship at..."},{"id":"ucb","name":"UC Berkeley"},{"id":"ucd","name":"UC Davis"},{"id":"uci","name":"UC Irvine"},{"id":"ucla","name":"UCLA"},{"id":"ucm","name":"UC Merced"},{"id":"ucr","name":"UC Riverside"},{"id":"ucsd","name":"UC San Diego"},{"id":"ucsf","name":"UCSF"},{"id":"ucsb","name":"UC Santa Barbara"},{"id":"ucsc","name":"UC Santa Cruz"},{"id":"ucop","name":"UC Office of the President"},{"id":"lbnl","name":"Lawrence Berkeley National Laboratory"},{"id":"anrcs","name":"UC Agriculture & Natural Resources"}],"query":{"q":"author:Perkins, Diana","sort":"rel","rows":"10","info_start":"0","start":"0","filters":{}},"count":137,"info_count":0,"infoResults":[],"searchResults":[{"id":"qt85g271k0","title":"39.1 DNA METHYLATION OF IMMUNE CELLS IN PERSONS AT CLINICAL HIGH RISK FOR PSYCHOSIS","abstract":"Abstract <h4>Background</h4> A dysregulated immune system is implicated in the development of psychotic disorders. Persons with schizophrenia have altered levels of circulating immune cell signaling molecules (cytokines), and elevation of specific cytokines predict conversion to psychosis in persons at clinical high risk. Whether these peripheral signals are a causal or a secondary phenomenon is unclear. But, subpopulations of circulating immune cells do regulate the brain from meningeal and perivascular locations influencing cognition, mood, and behavior, and thus may be relevant to schizophrenia vulnerability. Hematopoietic stem cells in the bone marrow differentiate into cascading subtypes depending on signals from other organs, especially the brain. For example, a monocyte subpopulation emerges with repeated social defeat that establish the persistence of anxiety-like behaviors; blocking their release or inhibiting their attachment to brain vascular endothelium prevents the emergence of anxiety-like behaviors. In humans, a similar monocyte subpopulation is associated with social isolation and other adversities including low SES, chronic stress, and bereavement. <h4>Methods</h4> The North American Prodrome Longitudinal Study (NAPLS2) is an eight-site observational study of predictors and mechanisms of conversion to psychosis The full cohort includes 763 at clinical high risk (CHR) based on the Criteria of Prodromal State (COPS) and 279 demographically similar unaffected comparison (UC) subjects. Methylation of whole blood DNA collected in PAXgene tubes at baseline was analyzed with the Illumina 450k array in a subgroup of 59 subjects who converted to psychosis (CHR-C), 84 CHR subjects followed for 2 years who did not develop psychosis (CHR-NC) and 67 unaffected subjects (UC). Our analyses focused on methylation of promoter regions of genes, associated with gene expression. Classifier construction used Coarse Approximation Linear Function (CALF) with bootstrapping of 1000 random 80% subsets with replacement to determine statistical likelihood. <h4>Results</h4> We found highly overlapping sets of differentially methylated promoter regions in CHR-C subjects compared to CHR-NC and to UC subjects. A set of 10 markers correctly classified CHR-C and CHR-NC subjects with high accuracy (AUC=0.94, 95% CI 0.89\u20130.98). Included was SIRT1, a gene that is upregulated with HSV reactivation. <h4>Discussion</h4> Circulating immune cells excerpt powerful influences on mood, cognition and behavior. An obvious example is the experience of most human with \u201Csickness syndrome\u201D, characterized by apathy, avolition, and withdrawal, and triggered by immune-cell-released cytokines producing an adaptive, resource conserving, behavioral response. While at an early stage, our findings further implicate immune system dysregulation as a mechanism in the development of psychosis.","content_type":"application/pdf","author_hide":null,"authors":[{"name":"Perkins, Diana","fname":"Diana","lname":"Perkins"},{"name":"Clark, Jeffries","fname":"Jeffries","lname":"Clark"},{"name":"Addington, Jean","fname":"Jean","lname":"Addington"},{"name":"Beardon, Carrie","fname":"Carrie","lname":"Beardon"},{"name":"Cadenhead, Kristin","fname":"Kristin","lname":"Cadenhead"},{"name":"Cannon, Tyrone","fname":"Tyrone","lname":"Cannon"},{"name":"Cornblatt, Barbara","fname":"Barbara","lname":"Cornblatt"},{"name":"Mathalon, Daniel","fname":"Daniel","lname":"Mathalon"},{"name":"McGlashan, Thomas","fname":"Thomas","lname":"McGlashan"},{"name":"Seidman, Larry","fname":"Larry","lname":"Seidman"},{"name":"Tsuang, Ming","email":"mtsuang@ucsd.edu","fname":"Ming","lname":"Tsuang","ORCID_id":"0000-0002-0076-5340"},{"name":"Walker, Elaine","fname":"Elaine","lname":"Walker"},{"name":"Woods, Scott","fname":"Scott","lname":"Woods"}],"supp_files":[{"type":"pdf","count":0},{"type":"image","count":0},{"type":"video","count":0},{"type":"audio","count":0},{"type":"zip","count":0},{"type":"other","count":0}],"thumbnail":{"width":121,"height":167,"asset_id":"c1a89740f2be8244d329319dacf0a575e667c9389e3af373246e3e12cef8f5c8","timestamp":1689402925,"image_type":"png"},"pub_year":2018,"genre":"article","rights":null,"peerReviewed":true,"unitInfo":{"displayName":"UC San Diego Previously Published Works","link_path":"ucsd_postprints"}},{"id":"qt5666t6qw","title":"SU127. Negative Symptoms in Youth at Clinical High Risk of Psychosis","abstract":"Abstract Background: Longitudinal studies examining youth at clinical high risk (CHR) of psychosis have predominantly focused on positive symptoms. However, youth at CHR often demonstrate persistent and significant negative symptoms, which have been reported to be predictive of conversion to psychosis. The goal of this study was to examine negative symptoms over time in youth at CHR of psychosis and compare baseline negative symptoms in those who convert to psychosis with those who did not convert. Methods: Youth at CHR (N = 764) were recruited for the North American Prodrome Longitudinal Study (NAPLS 2) at 8 sites across North America. Negative symptoms were rated on the Scale of Prodromal Symptoms (SOPS) at baseline, 6, 12, 18, and 24 months. Difference in prevalence of negative symptoms was assessed using Z test and change in negative symptom severity over time was assessed using repeated measures analysis of variance ANOVA. Wilcoxon rank sum test and 2-sample t test were utilized to compare baseline negative symptoms in converters vs nonconverters. Results: The mean total negative symptom score at baseline was 11.90 (SD = 9.80). A majority of participants (84.57%) had at least one negative symptom rated \u22653 at baseline. Negative symptom severity significantly decreased over time compared to baseline measures. Eighty-six participants converted in total. In participants with at least one negative symptom of moderate severity or above (N \u2265 3), nonconverters had lower severity ratings on expression of emotion (M = 1.49, SD = 1.47 vs M = 1.94, SD = 1.64, P = .02) and ideational richness (M = 1.23, SD = 1.37 vs M = 1.60, SD = 1.35, P = .04) compared to converters at baseline. In participants who completed 24 months of assessment and had negative symptom severity of moderate severity or above (N \u2265 3), nonconverters had significantly better expression of emotion (M = 1.40, SD = 1.51) compared to converters (M = 1.79, SD = 1.63, P = .03). Conclusion: First, this study demonstrated that the majority of youth at CHR have moderate to severe negative symptoms at baseline. Second, both decreased expression of emotion and decreased ideational richness was significantly more severe in participants who converted and may be indicative of later conversion to psychosis. Thus, early and persistent higher negative symptom scores may represent subsequent risk of conversion to psychosis.","content_type":"application/pdf","author_hide":null,"authors":[{"name":"Devoe, Daniel","fname":"Daniel","lname":"Devoe"},{"name":"Cadenhead, Kristen","fname":"Kristen","lname":"Cadenhead"},{"name":"Cannon, Tyrone","fname":"Tyrone","lname":"Cannon"},{"name":"Cornblatt, Barbara","fname":"Barbara","lname":"Cornblatt"},{"name":"McGlashan, Tom","fname":"Tom","lname":"McGlashan"},{"name":"Perkins, Diana","fname":"Diana","lname":"Perkins"},{"name":"Seidman, Larry J","fname":"Larry J","lname":"Seidman"},{"name":"Tsuang, Ming","email":"mtsuang@ucsd.edu","fname":"Ming","lname":"Tsuang","ORCID_id":"0000-0002-0076-5340"},{"name":"Walker, Elaine","fname":"Elaine","lname":"Walker"},{"name":"Woods, Scott","fname":"Scott","lname":"Woods"},{"name":"Bearden, Carrie","fname":"Carrie","lname":"Bearden"},{"name":"Mathalon, Daniel","fname":"Daniel","lname":"Mathalon"},{"name":"Addington, Jean","fname":"Jean","lname":"Addington"}],"supp_files":[{"type":"pdf","count":0},{"type":"image","count":0},{"type":"video","count":0},{"type":"audio","count":0},{"type":"zip","count":0},{"type":"other","count":0}],"thumbnail":{"width":121,"height":163,"asset_id":"4f75c4f2a44c9ede1a107b6e4d80f3a743cf5fc75d85f50da3598a9ef7e70728","timestamp":1689405155,"image_type":"png"},"pub_year":2017,"genre":"article","rights":null,"peerReviewed":true,"unitInfo":{"displayName":"UC San Diego Previously Published Works","link_path":"ucsd_postprints"}},{"id":"qt5jd2p259","title":"23. Omega-3 Fatty Acid Versus Placebo in a Clinical High-Risk Sample From the North American Prodrome Longitudinal Studies (NAPLS) Consortium","abstract":"Abstract Background: Omega-3 Fatty Acids (FAs), EPA (eicosapentaenoic acid) and DHA (Docosahexaenoic acid), are essential for normal brain development and may also have neuroprotective properties. Dietary supplementation of EPA and DHA has beneficial effects in medical illnesses as well as depression, bipolar disorder, and dementia. Abnormal FA metabolism may play a role in the etiology of psychiatric illness. Studies of erythrocytes and skin fibroblasts have shown reduced levels of FAs and phospholipids in schizophrenia. Studies of Omega-3FA supplementation in schizophrenia have been mixed. Amminger et al performed a randomized, double-blind, placebo-controlled trial in 81 subjects with prodromal symptoms of psychosis. The treatment consisted of 1.2g/day of Omega-3FAs (700\u2009mg EPA, 480\u2009mg DHA). After 12 weeks, 2 (4.9%) of 41 individuals in the Omega-3FA group and 11 of 40 (27.5%) in the placebo group converted to a psychotic disorder. Omega-3FAs also significantly reduced symptoms and improved functioning. The Aims of the current study were to replicate the Amminger study in Clinical High Risk (CHR) subjects from the NAPLS consortium. Methods: This was a 24-week, randomized, double-blind, placebo, fixed dose-controlled study of Omega-3FA versus placebo in 127 CHR subjects. The Omega-3FA compound contained a 2:1 proportion of EPA to DHA. The total dose was 740\u2009mg of EPA and 400\u2009mg of DHA. Baseline diet characterization was assessed using a systematic checklist that includes Omega-3FA foods. In addition, fasting erythrocyte FA composition was assessed. Results: Of the 127 CHR subjects recruited into the trial, 118 completed baseline assessment, and 70 (59%) completed the 6-month trial. Seven (10% Kaplan-Meier) subjects converted to psychosis during the 24 months. The rate of psychotic conversion did not differ in the Omega-3FA (13%) versus Placebo (8%) samples. Conversion to psychosis was predicted by low Omega-3FA rich foods in the diet (Wald Statistic = 4.96, P < .05). Although there were significant improvements in symptom and functioning over time in Mixed Model analyses, there were no significant group or Group \u00D7 Time interaction effects. Conclusion: The rate of conversion to psychosis in the present sample was lower than is typically observed in an at-risk population. Given the study attrition and low rate of conversion to psychosis, the trial was underpowered to replicate the conversion effect in the Amminger et al.\u2019s study. Despite the overall improvement in symptoms and functioning over time in all subjects, there was no clear evidence of a differential effect in the sample on Omega-3FA vs Placebo. Further work is needed to better tease out the role of diet and Omega-3FA in mental illness. The finding of a significant association between baseline diet low in Omega-3FA rich foods and later conversion to psychosis raises the question of whether it is possible to influence both physical and mental health with lifestyle choices including diet.","content_type":"application/pdf","author_hide":null,"authors":[{"name":"Cadenhead, Kristin","fname":"Kristin","lname":"Cadenhead"},{"name":"Addington, Jean","fname":"Jean","lname":"Addington"},{"name":"Cannon, Tyrone","fname":"Tyrone","lname":"Cannon"},{"name":"Cornblatt, Barbara","fname":"Barbara","lname":"Cornblatt"},{"name":"Mathalon, Daniel","fname":"Daniel","lname":"Mathalon"},{"name":"McGlashan, Tom","fname":"Tom","lname":"McGlashan"},{"name":"Perkins, Diana","fname":"Diana","lname":"Perkins"},{"name":"Seidman, Larry J","fname":"Larry J","lname":"Seidman"},{"name":"Tsuang, Ming","email":"mtsuang@ucsd.edu","fname":"Ming","lname":"Tsuang","ORCID_id":"0000-0002-0076-5340"},{"name":"Walker, Elaine","fname":"Elaine","lname":"Walker"},{"name":"Woods, Scott","fname":"Scott","lname":"Woods"}],"supp_files":[{"type":"pdf","count":0},{"type":"image","count":0},{"type":"video","count":0},{"type":"audio","count":0},{"type":"zip","count":0},{"type":"other","count":0}],"thumbnail":{"width":121,"height":167,"asset_id":"0d42bcaf8ad048fd0ee8123a8d5b3da501aedef669a69070369b824d8ac3e8d9","timestamp":1689404206,"image_type":"png"},"pub_year":2017,"genre":"article","rights":null,"peerReviewed":true,"unitInfo":{"displayName":"UC San Diego Previously Published Works","link_path":"ucsd_postprints"}},{"id":"qt53534296","title":"24.2 NEUROCOGNITIVE PROFILES IN THE PRODROME TO PSYCHOSIS IN NAPLS-1","abstract":"Abstract <h4>Background</h4> The vast majority of studies of neuropsychological (NP) functioning in Clinical High Risk (CHR) cohorts have examined group averages, possibly concealing a range of subgroups ranging from very impaired to high functioning. Our objective was to assess NP profiles and to explore associations with conversion to psychosis, functional and diagnostic outcome. <h4>Methods</h4> Data were acquired from 324 participants (mean age 18.4) in the first phase of the North American Prodrome Longitudinal Study (NAPLS-1), a multi-site consortium following individuals for up to 2\u00BD years. We applied Ward\u2019s method for hierarchical clustering data to 8 baseline neurocognitive measures, in 166 CHR individuals, 49 non-CHR youth with a family history of psychosis, and 109 healthy controls. We tested whether cluster membership was associated with conversion to psychosis, social and role functioning, and follow-up diagnosis. Analyses were repeated after data were clustered based on independently developed clinical decision rules. <h4>Results</h4> Four neurocognitive clusters were identified: Significantly Impaired (n=33); Mildly Impaired (n=82); Normal (n=145) and High (n=64). The Significantly Impaired subgroup demonstrated the largest deviations on processing speed and memory tasks and had a conversion rate of 58%, a 40% chance of developing a schizophrenia spectrum diagnosis (compared to 24.4% in the Mildly Impaired, and 10.3% in the other two groups combined), and significantly worse functioning at baseline and 12-months. Data clustered using clinical decision rules yielded similar results, pointing to high convergent validity. <h4>Discussion</h4> Despite extensive neuropsychological investigations within CHR cohorts, this is one of the first studies to investigate NP clustering profiles as a contributor to heterogeneity in outcome. Our results indicate that the four NP profiles vary substantially in their outcome, underscoring the relevance of cognitive functioning in the prediction of illness progression. Our findings tentatively suggest that individualized cognitive profiling should be explored in clinical settings.","content_type":"application/pdf","author_hide":null,"authors":[{"name":"Velthorst, Eva","fname":"Eva","lname":"Velthorst"},{"name":"Bearden, Carrie","fname":"Carrie","lname":"Bearden"},{"name":"Meyer, Eric","fname":"Eric","lname":"Meyer"},{"name":"Giuliano, Anthony","fname":"Anthony","lname":"Giuliano"},{"name":"Addington, Jean","fname":"Jean","lname":"Addington"},{"name":"Cadenhead, Kristin","fname":"Kristin","lname":"Cadenhead"},{"name":"Cannon, Tyrone","fname":"Tyrone","lname":"Cannon"},{"name":"Cornblatt, Barbara","fname":"Barbara","lname":"Cornblatt"},{"name":"Mcglashan, Thomas","fname":"Thomas","lname":"Mcglashan"},{"name":"Perkins, Diana","fname":"Diana","lname":"Perkins"},{"name":"Tsuang, Ming","email":"mtsuang@ucsd.edu","fname":"Ming","lname":"Tsuang","ORCID_id":"0000-0002-0076-5340"},{"name":"Walker, Elaine","fname":"Elaine","lname":"Walker"},{"name":"Woods, Scott","fname":"Scott","lname":"Woods"},{"name":"Seidman, Larry","fname":"Larry","lname":"Seidman"}],"supp_files":[{"type":"pdf","count":0},{"type":"image","count":0},{"type":"video","count":0},{"type":"audio","count":0},{"type":"zip","count":0},{"type":"other","count":0}],"thumbnail":{"width":121,"height":164,"asset_id":"657a3125df11cbcd556b3cf3a95485228ac64c40f2e47acd76e6f7fad3d1c789","timestamp":1689402809,"image_type":"png"},"pub_year":2018,"genre":"article","rights":null,"peerReviewed":true,"unitInfo":{"displayName":"UC San Diego Previously Published Works","link_path":"ucsd_postprints"}},{"id":"qt0t23x1cq","title":"59.4 Networks of Blood Analytes are Collectively Informative of Risk of Conversion to Schizophrenia","abstract":"Abstract Background: The presence and severity of attenuated-psychosis symptoms define a clinical high risk (CHR) population at elevated risk for psychotic disorders. The NAPLS project is a prospective study of mechanisms contributing to psychosis vulnerability in persons at CHR. Here we investigated a hypothesized role for the highly-integrated immune and redox systems in the development of psychosis. Methods: We examined expression of 143 plasma analytes from a subgroup of the NAPLS2 cohort, including 32 CHR with subsequent psychosis conversion, 40 CHR followed for 2 years without psychosis, and 35 unaffected subjects. We used a Luminex platform with analytes chosen to reflect immune, redox, hormonal, and metabolic system status, including many analytes previously associated with schizophrenia and psychosis risk. We applied correlation network analysis to discover potentially co-regulated networks associated with later development of psychosis. Results: Several robust (r > .75) and highly significant (P < .0001 after correction for multiple testing) correlation networks were found in all groups, including a network involving IL3, IL5, IL7, and IL13, and a network involving CCL5, BDNF, TSH, and PDGF. There were significantly fewer nodes in CHR-converters compared with CHR-nonconverters and unaffected subjects. In unaffected subjects, plasminogen activator inhibitor-1 (PAI-1) was highly correlated with matrix metallopeptidases (MMP) 7, 9 and 10 and CD40LG, this network was absent in CHR subjects, and in CHR-converters PAI-1 was robustly and significantly correlated with TIMP1, CCL13, and TIMP1. Conclusion: A pattern of robust and highly significant correlation networks in plasma analytes suggests shared regulatory mechanisms for the inter-correlated analytes. The lower number of correlated analytes in CHR subjects who converted to psychosis suggest a shift in regulation, as does the change in the correlation network involving PAI-1. PAI-1 is of interest given studies linking schizophrenia with reduced tissue plasminogen activator (tPA) and increases in negative regulators of tPA, including activation of both PAI-1and TIMP1 with oxidative stress. In addition, a recent study links toxoplasmosis infection and schizophrenia risk to a pathway involving PAI-1 and TIMP1. Patricio O\u2019Donnell, Pfizer Inc.","content_type":"application/pdf","author_hide":null,"authors":[{"name":"Jeffries, Clark","fname":"Clark","lname":"Jeffries"},{"name":"Perkins, Diana","fname":"Diana","lname":"Perkins"},{"name":"Addington, Jean","fname":"Jean","lname":"Addington"},{"name":"Bearden, Carrie","fname":"Carrie","lname":"Bearden"},{"name":"Cadenhead, Kristen","fname":"Kristen","lname":"Cadenhead"},{"name":"Cannon, Tyrone","fname":"Tyrone","lname":"Cannon"},{"name":"Cornblatt, Barbara","fname":"Barbara","lname":"Cornblatt"},{"name":"Mathalon, Daniel","fname":"Daniel","lname":"Mathalon"},{"name":"McGlashan, Tom","fname":"Tom","lname":"McGlashan"},{"name":"Seidman, Larry J","fname":"Larry J","lname":"Seidman"},{"name":"Tsuang, Ming","email":"mtsuang@ucsd.edu","fname":"Ming","lname":"Tsuang","ORCID_id":"0000-0002-0076-5340"},{"name":"Walker, Elaine","fname":"Elaine","lname":"Walker"},{"name":"Woods, Scott","fname":"Scott","lname":"Woods"}],"supp_files":[{"type":"pdf","count":0},{"type":"image","count":0},{"type":"video","count":0},{"type":"audio","count":0},{"type":"zip","count":0},{"type":"other","count":0}],"thumbnail":{"width":121,"height":167,"asset_id":"d7f57468db9e0db827d0c1e60b1022a1c2a6b060ce52f3cb5f499b566cb43147","timestamp":1689405387,"image_type":"png"},"pub_year":2017,"genre":"article","rights":null,"peerReviewed":true,"unitInfo":{"displayName":"UC San Diego Previously Published Works","link_path":"ucsd_postprints"}},{"id":"qt9cb1z9c2","title":"Common Data Elements for National Institute of Mental Health\u2013Funded Translational Early Psychosis Research","abstract":"The National Institutes of Health has established the PhenX Toolkit as a web-based resource containing consensus measures freely available to the research community. The National Institute of Mental Health (NIMH) has introduced the Mental Health Research Core Collection as part of the PhenX Toolkit and recently convened the PhenX Early Psychosis Working Group to generate the PhenX Early Psychosis Specialty Collection. The Working Group consisted of two complementary panels for clinical and translational research. We review the process, deliberations, and products of the translational research panel. The Early Psychosis Specialty Collection rationale for measure selection as well as additional information and protocols for obtaining each measure are available on the PhenX website (https://www.phenxtoolkit.org). The NIMH strongly encourages investigators to use instruments from the PhenX Mental Health Research Collections in NIMH-funded studies and discourages use of alternative measures to collect similar data without justification. We also discuss some of the potential advances that can be achieved by collecting common data elements across large-scale longitudinal studies of early psychosis.","content_type":"application/pdf","author_hide":null,"authors":[{"name":"\u00D6ng\u00FCr, Dost","fname":"Dost","lname":"\u00D6ng\u00FCr"},{"name":"Carter, Cameron S","email":"cscarter@ucdavis.edu","fname":"Cameron S","lname":"Carter"},{"name":"Gur, Raquel E","fname":"Raquel E","lname":"Gur"},{"name":"Perkins, Diana","fname":"Diana","lname":"Perkins"},{"name":"Sawa, Akira","fname":"Akira","lname":"Sawa"},{"name":"Seidman, Larry J","fname":"Larry J","lname":"Seidman"},{"name":"Tamminga, Carol","fname":"Carol","lname":"Tamminga"},{"name":"Huggins, Wayne","fname":"Wayne","lname":"Huggins"},{"name":"Hamilton, Carol","fname":"Carol","lname":"Hamilton"}],"supp_files":[{"type":"pdf","count":0},{"type":"image","count":0},{"type":"video","count":0},{"type":"audio","count":0},{"type":"zip","count":0},{"type":"other","count":0}],"thumbnail":{"width":121,"height":162,"asset_id":"18d1d24010d51f47cde8ae6a9e9eee3b6453f481299583d9a4f2f6003cdc6777","timestamp":1685603683,"image_type":"png"},"pub_year":2020,"genre":"article","rights":null,"peerReviewed":true,"unitInfo":{"displayName":"UC Davis Previously Published Works","link_path":"ucd_postprints"}},{"id":"qt8j42s24m","title":"Sex- and Age-Specific Deviations in Cerebellar Structure and Their Link With Symptom Dimensions and Clinical Outcome in Individuals at Clinical High Risk for Psychosis.","abstract":"BACKGROUND: The clinical high-risk (CHR) period offers a temporal window into neurobiological deviations preceding psychosis onset, but little attention has been given to regions outside the cerebrum in large-scale studies of CHR. Recently, the North American Prodrome Longitudinal Study (NAPLS)-2 revealed altered functional connectivity of the cerebello-thalamo-cortical circuitry among individuals at CHR; however, cerebellar morphology remains underinvestigated in this at-risk population, despite growing evidence of its involvement in psychosis. STUDY DESIGN: In this multisite study, we analyzed T1-weighted magnetic resonance imaging scans obtained from N = 469 CHR individuals (61% male, ages = 12-36 years) and N = 212 healthy controls (52% male, ages = 12-34 years) from NAPLS-2, with a focus on cerebellar cortex and white matter volumes separately. Symptoms were rated by the Structured Interview for Psychosis-Risk Syndromes (SIPS). The outcome by two-year follow-up was categorized as in-remission, symptomatic, prodromal-progression, or psychotic. General linear models were used for case-control comparisons and tests for volumetric associations with baseline SIPS ratings and clinical outcomes. STUDY RESULTS: Cerebellar cortex and white matter volumes differed between the CHR and healthy control groups at baseline, with sex moderating the difference in cortical volumes, and both sex and age moderating the difference in white matter volumes. Baseline ratings for major psychosis-risk dimensions as well as a clinical outcome at follow-up had tissue-specific associations with cerebellar volumes. CONCLUSIONS: These findings point to clinically relevant deviations in cerebellar cortex and white matter structures among CHR individuals and highlight the importance of considering the complex interplay between sex and age when studying the neuromaturational substrates of psychosis risk.","content_type":"application/pdf","author_hide":null,"authors":[{"name":"Woods, Scott","fname":"Scott","lname":"Woods"},{"name":"Cannon, Tyrone","fname":"Tyrone","lname":"Cannon"},{"name":"Walker, Elaine","fname":"Elaine","lname":"Walker"},{"name":"Sefik, Esra","fname":"Esra","lname":"Sefik"},{"name":"Boamah, Michelle","fname":"Michelle","lname":"Boamah"},{"name":"Addington, Jean","fname":"Jean","lname":"Addington"},{"name":"Cornblatt, Barbara","fname":"Barbara","lname":"Cornblatt"},{"name":"Keshavan, Matcheri","fname":"Matcheri","lname":"Keshavan"},{"name":"Perkins, Diana","fname":"Diana","lname":"Perkins"},{"name":"Stone, William","fname":"William","lname":"Stone"},{"name":"Mathalon, Daniel","email":"daniel.mathalon@ucsf.edu","fname":"Daniel","lname":"Mathalon"},{"name":"Bearden, Carrie","email":"cbearden@mednet.ucla.edu","fname":"Carrie","lname":"Bearden"},{"name":"Cadenhead, Kristin","email":"kcadenhead@ucsd.edu","fname":"Kristin","lname":"Cadenhead"},{"name":"Tsuang, Ming","email":"mtsuang@ucsd.edu","fname":"Ming","lname":"Tsuang"}],"supp_files":[{"type":"pdf","count":0},{"type":"image","count":0},{"type":"video","count":0},{"type":"audio","count":0},{"type":"zip","count":0},{"type":"other","count":0}],"thumbnail":{"width":121,"height":165,"asset_id":"f05a725d546a91e264392937a9ba4ff55f91b236eaa802323956c51ac63ed7d0","timestamp":1701271902,"image_type":"png"},"pub_year":2023,"genre":"article","rights":null,"peerReviewed":true,"unitInfo":{"displayName":"UC San Francisco Previously Published Works","link_path":"ucsf_postprints"}},{"id":"qt93m2x62j","title":"T116. PREDICTION OF REMISSION IN NON-CONVERTING INDIVIDUALS AT CLINICAL HIGH RISK FOR PSYCHOSIS","abstract":"Abstract <h4>Background</h4> The clinical high-risk period before a first episode of psychosis (CHR-P) has been widely studied in the past 30 years with the goal of understanding the development of psychosis. Despite the progress in understanding what factors are associated with conversion to psychosis from the CHR-P state, less attention has been paid to the individuals who do not transition to psychosis. It is estimated that approximately 75\u201380% of individuals do not go on to convert to psychosis from the CHR-P state and this group should not simply be characterized as the inverse of conversion. To date, only a handful of studies have examined the characteristics and predictors of those who do not convert to psychosis and ultimately either remit or continue to meet symptom-based CHR-P criteria. The present study took an exploratory empirical approach to determining potential factors that predict remission in non-converters. <h4>Methods</h4> Participants were drawn from the North American Prodrome Longitudinal Study (NAPLS2). Univariate Kaplan Meier survival analyses were performed on a pool of available demographic and clinical variables. Variables that were significant (p < 0.05) in the univariate analyses were then included in a multivariate Cox proportional hazard regression to predict remission. Remission was defined as all SOPS positive symptom subscale items rated as a 2 or lower at any given follow-up visit. <h4>Results</h4> A total of 359 participants from the NAPLS2 study who did not convert to psychosis and had data for at least the baseline and first follow-up visit and were included in this study. Of these participants, 174 met criteria for symptomatic remission. A total of 57 clinical variables were tested in univariate analyses and 14 of these variables met criteria for inclusion in the multivariate model. The variables included in the multivariate model were demographic variables (ethnicity, stressful life events), items from the Scale of Prodromal Symptoms (SOPS) (avolition, dysphoric mood), subtest scores from the MATRICS Cognitive Battery (speed of processing, verbal learning, verbal and non-verbal working memory, reasoning and problem solving, visual learning), one item from the Calgary Depression Scale for Schizophrenia (CDSS) (pathological guilt) and measures of functioning (GAF decline in past year, lowest GAF score in the past year). Overall, the multivariate model achieved a C-index of 0.64 (SE = 0.02) and p-value of 0.001 in predicting remission. In the multivariate model, significant covariates included stressful life events (HR = .95, p = .006), Hispanic ethnicity (HR = 1.45, p = .045), and avolition (HR = .89, p = .04). Covariates approaching significance included visual learning (HR = 1.02, p = .07), and GAF decline in the past year (HR = 1.01, p = .09). <h4>Discussion</h4> This study is the first to use a data-driven approach to systematically assess clinical and demographic predictors of symptomatic remission in individuals who do not convert to psychosis. The identified set of significant clinical variables is novel, suggesting that remission represents a unique clinical phenomenon and suggesting that further study is warranted to best understand factors contributing to resilience and recovery from the CHR-P period.","content_type":"application/pdf","author_hide":null,"authors":[{"name":"Worthington, Michelle","fname":"Michelle","lname":"Worthington"},{"name":"Addington, Jean","fname":"Jean","lname":"Addington"},{"name":"Bearden, Carrie","fname":"Carrie","lname":"Bearden"},{"name":"Cadenhead, Kristin","fname":"Kristin","lname":"Cadenhead"},{"name":"Cornblatt, Barbara","fname":"Barbara","lname":"Cornblatt"},{"name":"Mathalon, Daniel","fname":"Daniel","lname":"Mathalon"},{"name":"McGlashan, Thomas","fname":"Thomas","lname":"McGlashan"},{"name":"Perkins, Diana","fname":"Diana","lname":"Perkins"},{"name":"Seidman, Larry","fname":"Larry","lname":"Seidman"},{"name":"Tsuang, Ming","email":"mtsuang@ucsd.edu","fname":"Ming","lname":"Tsuang","ORCID_id":"0000-0002-0076-5340"},{"name":"Walker, Elaine","fname":"Elaine","lname":"Walker"},{"name":"Woods, Scott","fname":"Scott","lname":"Woods"},{"name":"Cannon, Tyrone","fname":"Tyrone","lname":"Cannon"}],"supp_files":[{"type":"pdf","count":0},{"type":"image","count":0},{"type":"video","count":0},{"type":"audio","count":0},{"type":"zip","count":0},{"type":"other","count":0}],"thumbnail":{"width":121,"height":163,"asset_id":"dc5330705c0284aba97b14187054fe8793f35faf9fe378706165514a92dfa495","timestamp":1689401763,"image_type":"png"},"pub_year":2020,"genre":"article","rights":null,"peerReviewed":true,"unitInfo":{"displayName":"UC San Diego Previously Published Works","link_path":"ucsd_postprints"}},{"id":"qt3qn67694","title":"S244. CHARACTERIZING OUTCOMES OF CLINICAL HIGH-RISK NON-CONVERTERS USING GROUP-BASED TRAJECTORY MODELING","abstract":"Abstract <h4>Background</h4> The development of the clinical high-risk (CHR) prodromal criteria has facilitated advancement in understanding conversion to psychosis and has provided opportunities for early intervention and treatment for these individuals. However, the majority of CHR cases do not meet full criteria for conversion, yet continue to experience clinically significant symptoms and impairment in daily functioning. It is likely that many of these individuals would also benefit from additional intervention and treatment, but the outcomes and needs of these \u201Cnon-converters\u201D are not well characterized. Identifying common longitudinal patterns of symptoms and functioning of non-converters would support the identification of individuals who continue to require treatment and tailoring of services to their specific needs. <h4>Methods</h4> We used group-based trajectory modeling to identify common longitudinal symptom and functioning trajectories among CHR cases (N=561) in the second phase of the North American Prodrome Longitudinal Study (NAPLS2). Covariant trajectories of symptoms (including positive, negative, disorganized, and general) and functioning (including role and social) were examined. Models were tested for replicability in an independent sample of CHR cases (N=291) from the first phase of NAPLS (NAPLS1). <h4>Results</h4> We identified a subgroup of individuals who exhibited symptom remission and functioning within the normal range, as well as at least two additional subgroups that exhibited different patterns of ongoing, clinically significant symptoms and functional deficits. <h4>Discussion</h4> We are currently investigating the validity of these subgroups by assessing their association with a variety of risk factors and biomarkers.","content_type":"application/pdf","author_hide":null,"authors":[{"name":"Allswede, Dana","fname":"Dana","lname":"Allswede"},{"name":"Cannon, Tyrone","fname":"Tyrone","lname":"Cannon"},{"name":"Addington, Jean","fname":"Jean","lname":"Addington"},{"name":"Bearden, Carrie","fname":"Carrie","lname":"Bearden"},{"name":"Cadenhead, Kristin","fname":"Kristin","lname":"Cadenhead"},{"name":"Cornblatt, Barbara","fname":"Barbara","lname":"Cornblatt"},{"name":"Mathalon, Daniel","fname":"Daniel","lname":"Mathalon"},{"name":"Thomas, McGlashan","fname":"McGlashan","lname":"Thomas"},{"name":"Perkins, Diana","fname":"Diana","lname":"Perkins"},{"name":"Seidman, Larry","fname":"Larry","lname":"Seidman"},{"name":"Tsuang, Ming","email":"mtsuang@ucsd.edu","fname":"Ming","lname":"Tsuang","ORCID_id":"0000-0002-0076-5340"},{"name":"Walker, Elaine","fname":"Elaine","lname":"Walker"},{"name":"Woods, Scott","fname":"Scott","lname":"Woods"}],"supp_files":[{"type":"pdf","count":0},{"type":"image","count":0},{"type":"video","count":0},{"type":"audio","count":0},{"type":"zip","count":0},{"type":"other","count":0}],"thumbnail":{"width":121,"height":167,"asset_id":"91f5493df01c833748ff81171223dc3aaddff5f5cb4c273ec53d8300366ba731","timestamp":1689403042,"image_type":"png"},"pub_year":2018,"genre":"article","rights":null,"peerReviewed":true,"unitInfo":{"displayName":"UC San Diego Previously Published Works","link_path":"ucsd_postprints"}},{"id":"qt160961tz","title":"SU127. Negative Symptoms in Youth at Clinical High Risk of Psychosis","abstract":"Abstract Background: Longitudinal studies examining youth at clinical high risk (CHR) of psychosis have predominantly focused on positive symptoms. However, youth at CHR often demonstrate persistent and significant negative symptoms, which have been reported to be predictive of conversion to psychosis. The goal of this study was to examine negative symptoms over time in youth at CHR of psychosis and compare baseline negative symptoms in those who convert to psychosis with those who did not convert. Methods: Youth at CHR (N = 764) were recruited for the North American Prodrome Longitudinal Study (NAPLS 2) at 8 sites across North America. Negative symptoms were rated on the Scale of Prodromal Symptoms (SOPS) at baseline, 6, 12, 18, and 24 months. Difference in prevalence of negative symptoms was assessed using Z test and change in negative symptom severity over time was assessed using repeated measures analysis of variance ANOVA. Wilcoxon rank sum test and 2-sample t test were utilized to compare baseline negative symptoms in converters vs nonconverters. Results: The mean total negative symptom score at baseline was 11.90 (SD = 9.80). A majority of participants (84.57%) had at least one negative symptom rated \u22653 at baseline. Negative symptom severity significantly decreased over time compared to baseline measures. Eighty-six participants converted in total. In participants with at least one negative symptom of moderate severity or above (N \u2265 3), nonconverters had lower severity ratings on expression of emotion (M = 1.49, SD = 1.47 vs M = 1.94, SD = 1.64, P = .02) and ideational richness (M = 1.23, SD = 1.37 vs M = 1.60, SD = 1.35, P = .04) compared to converters at baseline. In participants who completed 24 months of assessment and had negative symptom severity of moderate severity or above (N \u2265 3), nonconverters had significantly better expression of emotion (M = 1.40, SD = 1.51) compared to converters (M = 1.79, SD = 1.63, P = .03). Conclusion: First, this study demonstrated that the majority of youth at CHR have moderate to severe negative symptoms at baseline. Second, both decreased expression of emotion and decreased ideational richness was significantly more severe in participants who converted and may be indicative of later conversion to psychosis. Thus, early and persistent higher negative symptom scores may represent subsequent risk of conversion to psychosis.","content_type":"application/pdf","author_hide":null,"authors":[{"name":"Devoe, Daniel","fname":"Daniel","lname":"Devoe"},{"name":"Cadenhead, Kristen","fname":"Kristen","lname":"Cadenhead"},{"name":"Cannon, Tyrone","fname":"Tyrone","lname":"Cannon"},{"name":"Cornblatt, Barbara","fname":"Barbara","lname":"Cornblatt"},{"name":"McGlashan, Tom","fname":"Tom","lname":"McGlashan"},{"name":"Perkins, Diana","fname":"Diana","lname":"Perkins"},{"name":"Seidman, Larry J","fname":"Larry J","lname":"Seidman"},{"name":"Tsuang, Ming","email":"mtsuang@ucsd.edu","fname":"Ming","lname":"Tsuang","ORCID_id":"0000-0002-0076-5340"},{"name":"Walker, Elaine","fname":"Elaine","lname":"Walker"},{"name":"Woods, Scott","fname":"Scott","lname":"Woods"},{"name":"Bearden, Carrie","fname":"Carrie","lname":"Bearden"},{"name":"Mathalon, Daniel","fname":"Daniel","lname":"Mathalon"},{"name":"Addington, Jean","fname":"Jean","lname":"Addington"}],"supp_files":[{"type":"pdf","count":0},{"type":"image","count":0},{"type":"video","count":0},{"type":"audio","count":0},{"type":"zip","count":0},{"type":"other","count":0}],"thumbnail":{"width":121,"height":166,"asset_id":"e6380432417ccd93c81ccffd3e1f75bf548098163e748c149cb817085c9de04c","timestamp":1689405505,"image_type":"png"},"pub_year":2017,"genre":"article","rights":null,"peerReviewed":true,"unitInfo":{"displayName":"UC San Diego Previously Published Works","link_path":"ucsd_postprints"}}],"facets":[{"display":"Type of Work","fieldName":"type_of_work","facets":[{"value":"article","count":137,"displayName":"Article"},{"value":"monograph","count":0,"displayName":"Book"},{"value":"dissertation","count":0,"displayName":"Theses"},{"value":"multimedia","count":0,"displayName":"Multimedia"}]},{"display":"Peer Review","fieldName":"peer_reviewed","facets":[{"value":"1","count":137,"displayName":"Peer-reviewed only"}]},{"display":"Supplemental Material","fieldName":"supp_file_types","facets":[{"value":"video","count":0,"displayName":"Video"},{"value":"audio","count":0,"displayName":"Audio"},{"value":"images","count":0,"displayName":"Images"},{"value":"zip","count":0,"displayName":"Zip"},{"value":"other files","count":0,"displayName":"Other files"}]},{"display":"Publication Year","fieldName":"pub_year","range":{"pub_year_start":null,"pub_year_end":null}},{"display":"Campus","fieldName":"campuses","facets":[{"value":"ucb","count":0,"displayName":"UC Berkeley"},{"value":"ucd","count":1,"displayName":"UC Davis"},{"value":"uci","count":11,"displayName":"UC Irvine"},{"value":"ucla","count":101,"displayName":"UCLA"},{"value":"ucm","count":0,"displayName":"UC Merced"},{"value":"ucr","count":0,"displayName":"UC Riverside"},{"value":"ucsd","count":127,"displayName":"UC San Diego"},{"value":"ucsf","count":92,"displayName":"UCSF"},{"value":"ucsb","count":4,"displayName":"UC Santa Barbara"},{"value":"ucsc","count":3,"displayName":"UC Santa Cruz"},{"value":"ucop","count":0,"displayName":"UC Office of the President"},{"value":"lbnl","count":7,"displayName":"Lawrence Berkeley National Laboratory"},{"value":"anrcs","count":0,"displayName":"UC Agriculture & Natural Resources"}]},{"display":"Department","fieldName":"departments","facets":[{"value":"lbnl_bs","count":1,"displayName":"BioSciences"},{"value":"lbnl_cs","count":3,"displayName":"Computing Sciences"},{"value":"ucsdpsych","count":116,"displayName":"Department of Psychiatry, UCSD"},{"value":"lbnl_ees","count":5,"displayName":"Earth & Environmental Sciences"},{"value":"ucsdsom","count":125,"displayName":"School of Medicine"},{"value":"uclapsych","count":92,"displayName":"UCLA Department of Psychology"}]},{"display":"Journal","fieldName":"journals","facets":[]},{"display":"Discipline","fieldName":"disciplines","facets":[]},{"display":"Reuse License","fieldName":"rights","facets":[{"value":"CC BY","count":3,"displayName":"BY - Attribution required"}]}]};</script> <script src="/js/vendors~app-bundle-7424603c338d723fd773.js"></script> <script src="/js/app-bundle-8362e6d7829414ab4baa.js"></script> </body> </html>